Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2010

The Expression of Matrix Metalloproteinase-9 and -2 in Olfactory
Injury and Recovery
Stephen Bakos
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Physiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/143

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Stephen R. Bakos
All Rights Reserved

2010

THE EXPRESSION OF MATRIX METALLOPROTEINASE-9 AND -2 IN OLFACTORY
INJURY AND RECOVERY

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University

By

Stephen Robert Bakos
B.A., University of Colorado at Boulder, 2005

Director: Richard M. Costanzo
Professor, Department of Physiology and Biophysics

Virginia Commonwealth University
Richmond, Virginia
September, 2010

Acknowledgement

The past three years would not have been possible had it not been for the
support, guidance, and encouragement of many people. Their friendship has made my
time in the laboratory both entertaining and enjoyable. First, I would like to thank my
advisor Dr. Richard Costanzo who kept me focused on my project and yet allowed me
to pursue many side projects. I am also appreciative to those who have served on my
committee: Drs. Clive Baumgarten, John DeSimone, Helen Fillmore, John Povlishock,
and Dorne Yager. Your technical advice and insight have helped tremendously in
propelling this project forward. A special thanks goes to Dr. Jim Schwob at Tufts
University for the research collaboration and allowing me to visit Boston for two weeks. I
am also grateful to Dr. Gordon Archer and the MD/PhD program for affording me the
opportunity to pursue my two interests in life: research and medicine.
A special thanks to members of the Povlishock lab including John Greer and Sue
Walker, who were extremely helpful with the cellular localization studies. I am grateful to
several people who gave critical reviews of the thesis: Clayton Bauer, Dr. Linda
Costanzo, Birch “Blaze” Goldston, Francis Saccoccio, Carissa Strane, and Julie Ziobro.
I would also like to thank current and former members of the Costanzo lab including
Heather Cross, Aaron Schatz, and Vinay Somashekar and all others who have been in
the lab during my tenure. In addition, a special thanks to Justin McClain and Nick Pullen

ii

for sharing their knowledge of matrix metalloproteinases and humorous views on
research and life.
I would not be where I am today had it not been for the love and support of my
parents Brian and Elizabeth Randolph. Even when times were tough, you always
provided me with the resources I needed to succeed in my education and life. Also a
special thanks to my in-laws, Tom and Joan Kolenich, who have been a great new
family for me. To my wife Kristine, you have been supportive in both my medical and
research training and I would not be here today without your advice and love. For this, I
am grateful to have you in my life.
Finally, this dissertation is dedicated in memory to Paul S. Bakos, who taught me
the value of hard work and to never give up, regardless of the challenge.

iii

Table of Contents
Page
Acknowledgement .................................................................................................ii
List of Tables....................................................................................................... vii
List of Figures..................................................................................................... viii
List of Common Abbreviations ..............................................................................x
Abstract ................................................................................................................xi
Chapter
1 Introduction to the Olfactory System ......................................................... 1
1.1 The olfactory system ........................................................................ 1
1.1.1 The anatomy of olfaction........................................................ 2
1.1.2 Topographical organization of the olfactory system ............... 4
1.1.3 Turnover and replacement of olfactory neurons .................... 5
1.1.4 Olfactory injury and recovery ................................................. 8
1.2 Introduction to the matrix metalloproteinases................................. 10
1.2.1 MMP structure and domains ................................................ 11
1.2.2 Activation of MMPs .............................................................. 13
1.2.3 MMPs in the normal CNS .................................................... 14
1.2.4 The role of MMPs in CNS injury and recovery ..................... 15
1.3 Project goals, hypotheses, and specific aims................................. 17

iv

2 Expression of Matrix Metalloproteinase-9 and -2 Following Olfactory
Nerve Transection ................................................................................... 22
2.1 Introduction .................................................................................... 22
2.2 Materials and Methods................................................................... 24
2.3 Results ........................................................................................... 30
2.4 Discussion...................................................................................... 48
3 MMP-9 is Associated with the Acute Inflammatory Response Following
Olfactory Nerve Transection .................................................................... 52
3.1 Introduction .................................................................................... 52
3.2 Material and Methods..................................................................... 53
3.3 Results ........................................................................................... 56
3.4 Discussion...................................................................................... 68
4 Matrix Metalloproteinase-9 and -2 Expression in the Olfactory Bulb
Following Methyl Bromide Gas Exposure ................................................ 72
4.1 Introduction .................................................................................... 72
4.2 Materials and Methods................................................................... 74
4.3 Results ........................................................................................... 77
4.4 Discussion...................................................................................... 92
5 The Peak Expression of MMP-2 Following Nerve Transection is
Dependent on Reinnervation of the Olfactory Bulb.................................. 97
5.1 Introduction .................................................................................... 97
5.2 Materials and Methods................................................................... 98
5.3 Results ......................................................................................... 102

v

5.4 Discussion.................................................................................... 118
6 General Discussions ............................................................................. 122
6.1 Summary of important findings .................................................... 122
6.2 Future Directions.......................................................................... 126
6.3 Significance of this project ........................................................... 128
Literature Cited................................................................................................. 130
Vita ................................................................................................................... 156

vi

List of Tables
Page
Table 1.1: The vertebral matrix metalloproteinases ........................................... 12
Table 2.1: Table summarizing the significant Western blot recovery points
compared to CTRL for OMP, MMP-9, and MMP-2 ....................................... 47
Table 4.1: Average number of MMP-9 labeled cells and areas of OB layers ..... 90
Table 4.2: Table summarizing the significant Western blot recovery points
compared to CTRL for MMP-9, MMP-2, OMP, and GFAP............................ 91
Table 5.1: Table summarizing the significant Western blot recovery points
compared to CTRL for OMP and MMP-2.................................................... 117

vii

List of Figures
Page
Figure 1.1: Topographical organization of the olfactory system ........................... 6
Figure 2.1: Diagram illustrating the NTx procedure and tissue collection for
Western blot analysis.................................................................................... 25
Figure 2.2: Comparison of the OB from CTRL and NTx mice ............................ 31
Figure 2.3: Injury-related changes in OMP expression in the OB following NTx 33
Figure 2.4: Changes in P2 odorant receptor projections following NTx.............. 35
Figure 2.5: OMP expression in CTRL and NTx bulbs demonstrating changes in
glomerular morphology ................................................................................. 37
Figure 2.6: Changes in MMP-9 expression in the OB following NTx.................. 41
Figure 2.7: Gelatin zymography illustrating changes in the pro and active forms of
MMP-9 following NTx.................................................................................... 43
Figure 2.8: Changes in MMP-2 levels in the OB following NTx .......................... 45
Figure 3.1: MMP-9 is localized only to the NTx bulb .......................................... 58
Figure 3.2: Colocalization of MMP-9 with neutrophilic makers in the OB following
NTx ............................................................................................................... 60
Figure 3.3: DAB and hematoxylin staining demonstrates that neutrophils contain
MMP-9 in the OB following NTx .................................................................... 62
Figure 3.4: Injury related changes in CD68 positive cells following NTx ............ 64
Figure 3.5: CD68 positive cells do not contain MMP-9 following NTx ................ 66

viii

Figure 4.1: Changes in MMP-9 and MMP-2 protein expression in the OB
following MeBr .............................................................................................. 79
Figure 4.2: Comparison of MMP-9 expression in the OB and frontal cortex
following MeBr .............................................................................................. 81
Figure 4.3: Changes in OMP and glial fibrillary acidic protein in the OB following
MeBr ............................................................................................................. 84
Figure 4.4: Coronal sections of the mouse OB following MeBr .......................... 86
Figure 4.5: Localization of MMP-9 to inflammatory cells in the OB at day 5....... 88
Figure 5.1: Comparison of MMP-2 labeling in CTRL and transected OB ......... 103
Figure 5.2: Teflon barrier blocks regenerated axons from contacting the OB .. 106
Figure 5.3: Comparison of P2 axonal projections at day 35 following NTx or NTxTB ............................................................................................................... 108
Figure 5.4: Changes in OMP expression following NTx-TB ............................. 111
Figure 5.5: Expression of MMP-2 following NTx-TB......................................... 113
Figure 5.6: Regenerated axons do not express MMP-2 following NTx-TB....... 115
Figure 6.1: Diagram illustrating the temporal correlation between MMP-9 and
degeneration, and MMP-2 and the onset of reinnervation .......................... 124

ix

List of Common Abbreviations

CNS
CPA
o
C
ECM
EPL
GCL
GL
IPL
MeBr
ML
MMP
NL
NTx
NTx-TB
OB
OE
OMP
OSN
V

Central Nervous System
Cyclophilin A
Degree Celsius
Extracellular matrix
External Plexiform Layer
Granule Cell Layer
Glomerular Layer
Internal Plexiform Layer
Methyl Bromide Gas
Mitral Layer
Matrix Metalloproteinase
Nerve Layer
Nerve Transection
Nerve Transection with Teflon Barrier
Olfactory Bulb
Olfactory Epithelium
Olfactory Marker Protein
Olfactory Sensory Neuron
Volt

x

Abstract

THE EXPRESSION OF MATRIX METALLOPROTEINASE-9 AND -2 IN OLFACTORY
INJURY AND RECOVERY
By Stephen Robert Bakos, B.A.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2010
Director: Richard M. Costanzo
Professor, Physiology and Biophysics

The olfactory system has the remarkable capacity for neurogenesis following
injury. However, the molecular mechanisms important for reinnervation of the olfactory
bulb (OB) remain unknown. The matrix metalloproteinases (MMPs) are important
components in many central nervous system (CNS) injury paradigms, yet remain
unexplored in olfactory injury and recovery. To address the role of MMPs, the temporal
expressions of MMP-9 and MMP-2 were examined in 3 olfactory injury models: nerve
transection (NTx), methyl bromide gas (MeBr) exposure, and nerve transection with
Teflon barrier (NTx-TB). Each injury model represents a different degree of olfactory
injury and neuronal recovery. In NTx, sensory axons are lesioned, leading to neuronal
degeneration and subsequent reinnervation of the OB. MeBr exposure damages the cell
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bodies of sensory neurons in the peripheral olfactory epithelium (OE), leading to
degeneration and reinnervation of the OB without direct trauma to the OB. In NTx-TB,
sensory axons are lesioned and a barrier is inserted following injury that blocks
regenerated neurons from reinnervation of the OB.
Following NTx, MMP-9 increased immediately in the OB and was localized to
neutrophils, an inflammatory leukocyte. The elevated levels of MMP-9 corresponded to
neuronal degeneration. To confirm this relationship, MMP-9 expression was measured
following MeBr injury. MMP-9 increased during neuronal degeneration in the OB and
was localized to neutrophils in the area of sensory axon degradation. These
experiments demonstrated that MMP-9 is important for both neuronal degeneration and
the acute inflammatory response following olfactory injury.
In NTx injury, MMP-2 expression peaked at day 7 and corresponded to the
transition between degeneration and reinnervation of the OB. MMP-2 was localized to
the granule cell and external plexiform layers in control and day 7 bulbs. Following
NTx-TB, MMP-2 remained low and was not expressed by regenerated axons. The
absence of a MMP-2 peak in the NTx-TB injury suggests that this peak depends on
reinnervation of the OB.
This study demonstrates a temporal correlation between MMP-9 and
degeneration and MMP-2 and reinnervation following olfactory injury. These findings
provide new insight into the molecular mechanisms underlying olfactory nerve injury.
Modulation of MMPs could provide novel therapeutic interventions to improve neuronal
recovery following injury.

xii

Chapter 1
Introduction to the Olfactory System

1.1 The olfactory system
Among sensory systems in the body, olfaction is unique, yet remains largely
overlooked by both society and the scientific community. To interact and receive
information about the external environment, humans depend less on the olfactory
system than the visual and auditory systems (Malnic et al., 2004). However, as the
French author Marcel Proust eloquently described in Remembrance of All Things Past,
a simple odor can evoke vivid memories of past events. This experience, termed the
Proust phenomenon, illustrates how olfactory stimuli are strong cues of autobiographical
memories.
Although olfaction is often unnoticed in the daily experience of humans, anosmia
(loss of smell) can be detrimental to the quality of life. Patients with olfactory dysfunction
often suffer from depression and are unable to detect hazards such as smoke, gas
leaks, and spoiled foods (Deems et al., 1991; Miwa et al., 2001; Santos et al., 2004;
Seiden, 1997). Currently, few therapeutic options are available for anosmic patients,
which illustrates the need for further studies in olfactory injury and recovery.
The 19th century neuroscientists, Golgi, Cajal, and Retzius, were the first to
examine the anatomy of the olfactory system. Later in the 20th century, researchers
discovered a unique property of olfactory sensory neurons (OSN). These neurons
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regenerate throughout life, the only nerves in the central nervous system (CNS) with
this capability. Subsequent studies demonstrated that OSNs regenerated following
injury, making the olfactory system a unique CNS injury and recovery model.

1.1.1 The anatomy of olfaction
The olfactory epithelium (OE) is the peripheral component of olfaction and is
located along the roof of the nasal cavity. It consists of three main cell types: OSNs,
supporting cells, and basal cells (Cuschieri and Bannister, 1975; Morrison and
Costanzo, 1992; Graziadei and Monti Graziadei, 1979). The OSNs are located along
the basal or middle portion of the OE, depending on their age. Younger neurons tend to
located along the basal aspect of the OE, while older neurons move towards the middle
(Graziadei and Monti Graziadei, 1977). These bipolar neurons project an unbranched
dendritic process to the apical epithelium that ends in a swelling termed the olfactory
knob. Extending from this knob are 10 to 25 cilia, which express the receptor that
interacts with odorant molecules in the nasal cavity (Morrison and Costanzo, 1990). The
mechanism of odorant and receptor interaction remains unknown, although supporting
cells secrete small proteins into the mucus that are thought to assist in odor detection
(Pevsner et al., 1985).
There are two main types of supporting cells in the OE: Bowman’s glands and
sustentacular cells. These cells provide a supportive environment for the unprotected
dendrites in the nasal cavity. Bowman’s glands secrete mucus that prevents drying of
the OE and contains ions that may enhance olfactory function (Morrison and Costanzo,
1992; Getchell et al., 1984). The sustentacular cells phagocytize debris and have a
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variety of P450 enzymes that degrade toxins in the nasal cavity (Chen et al., 1992; Ding
and Coon, 1988). Although Bowman’s glands and sustentacular cells maintain a
supportive environment, the OSNs require constant turnover. Basal cells in the OE
differentiate into new neurons and are responsible for maintaining the neuronal
population during normal turnover (Schwartz et al., 1991; Calof and Chikaraishi, 1989).
Sensory axons, the smallest in the CNS (0.7 to 1.0 μm in diameter), exit the OE
basally into the basal lamina (reviewed in Farbman, 1992). These axons converge to
form fascicles that are blanketed by olfactory ensheathing cells. The fascicles pass
through foramina of the cribriform plate and project to the olfactory bulb (OB). The OB
consists of six morphologic layers (superficial to deep): nerve (NL), glomerular (GL),
external plexiform (EPL), mitral (ML), internal plexiform (IPL), and granule cell (GCL).
The axons of the OSNs form the NL and terminate on the dendrites of second order
neurons (e.g., mitral and tufted cells) in a spherical neuropil called the glomerulus. The
axons of the second order neurons serve as the main output of the OB to structures in
the cerebral cortex (Doty, 2009). The anatomical organization of the olfactory system is
unique in that it is the only sensory system without a primary thalamic relay. As axons
leave the OB, via the olfactory tract, they project to cortical areas collectively termed the
olfactory cortex. This region includes the anterior olfactory nucleus, piriform cortex,
anterior cortical nucleus of the amygdala, periamygdaloid complex, and the rostral
entorhinal cortex. The olfactory cortex serves to identify odors, while also associating
the odors with specific emotions and memories. Although the olfactory cortex is
important in the identification of odors, it is thought that odor encoding begins in the OE
and OB.
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1.1.2 Topographical organization of the olfactory system
Many sensory systems, such as vision and somatosensation, are highly
organized to detect and interpret stimuli in the environment. The visual system sends
information from the retina along neuronal pathways to the lateral geniculate body
(LGB) of the thalamus. The LGB has six layers, with layers 2, 3 and 5 receiving input
from the ipsilateral retina, while layers 1, 4 and 6 from the contralateral retina. Further
topographical organization is found in the striate cortex of the occipital lobe. This
structure contains layers that correspond to specific regions of the visual field. In the
sematosensory cortex, regions of the body project to specific locations in the postcentral
gyrus, often represented as the sensory homunculus.
Similar to vision and somatosensation, the olfactory system is topographically
organized to detect and discriminate odors (Figure 1.1). The rodent genome contains
over 1000 genes dedicated to encoding unique G-protein olfactory receptors (Buck and
Axel, 1991; Zhang and Firestein, 2002). The olfactory receptors are randomly dispersed
within 4 distinct zones of the OE (Strotmann et al., 1992; Vassar et al., 1993). These
zones are arranged along the dorsoventral and medioventral axes of the epithelium and
project to precise regions in the bulb. The olfactory receptors respond to a variety of
odors, but at different intensities and send electrical stimuli to the OB. Mombaerts et al.
(1996) demonstrated that a subclass of sensory receptor neurons, expressing one
olfactory receptor in the OE, send axons to one or two specific glomeruli in the OB. The
pattern of glomerular activation by an odorant may be important for the olfactory cortex
to interpret and identify odor stimuli.
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1.1.3 Turnover and replacement of olfactory neurons
Early neuroscientists believed that CNS recovery was limited because mature
neurons lacked the ability to regenerate. Since peripheral nerves were observed to
regenerate, early researchers concluded that mature CNS neurons lost this intrinsic
ability after development. This idea went largely uncontested for over a century until
mitotically active basal cells were observed to generate new neurons in the OE
(Graziadei and Monti Graziadei, 1978).
The turnover of OSNs is thought to occur every 30-45 days, however longer
periods have been reported (Graziadei and Monti Graziadei, 1978; Hinds et al., 1984;
Mackay-Sim and Kittel, 1991). The continual replacement of neurons may be necessary
because the dendritic processes of OSNs are exposed to mechanical trauma, toxic
compounds, and infectious diseases in the nasal cavity. The OSNs are replaced by
globose basal cells in the OE, maintaining the neuronal population throughout life
(Graziadei and Monti Graziadei, 1979; Schwartz et al., 1991; Calof and Chikaraishi,
1989). The new OSNs send axons to the OB and reestablish functional synaptic
connections with second order neurons (Graziadei and DeHan, 1973). Normal turnover
of OSNs maintains the topographical organization of the olfactory system until old age
(Costanzo and Kobayashi, 2010).
The olfactory system provides a unique model to study CNS neurogenesis due to
its capacity to regenerate OSNs following injury. Graziadei and Hans (1973)
demonstrated that following olfactory nerve transection (NTx), there is a rapid and
complete degeneration of OSNs. Neuronal degeneration is first observed along the
rostro-ventral axis of the OB and subsequently extends to the dorso-caudal region
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Figure 1.1: Topographical organization of the olfactory system1

Figure 1.1: Topographical organization of the olfactory system. A subclass of sensory
neurons send axons through the CP to one specific glomerulus (G) in the OB. These
axons terminate on dendrites of second order neurons. The axons of second order
neurons project to structures in the olfactory cortex. CP: cribriform plate; G: glomerulus;
OB: olfactory bulb.
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(Graziadei and Monti Graziadei, 1980). Glial cells in the OB enlarge following injury and
phagocytize axonal debris, while sustentacular cells in the OE engulf apoptotic neuronal
cell bodies (Graziadei and Monti Graziadei, 1980; Suzuki et al., 1995; Suzuki et al.,
1996).

1.1.4 Olfactory injury and recovery
The morphology of the OB remains largely intact following NTx, however the
dendrites of second order neurons are swollen (Graziadei and Monti Graziadei, 1980).
In the OE, basal cells increase their mitotic activity and differentiate into new neurons
(Graziadei, 1973). These regenerated neurons send axons to the NL and GL of the OB.
The time course of neuronal degeneration and reinnervation following NTx varies
among species. In frogs, degeneration of sensory axons occurs over a two week period,
while neuronal regeneration is first measured by day 20 (Graziadei and DeHan, 1973).
Regeneration of sensory neurons in pigeons is evident by 32 days following NTx.
(Jennings et al., 1995). In rodents, degeneration is evident 15-24 hours following injury
and peaks between days 3 and 4. Regenerated axons are apparent in the bulb by day
20, but shorter recovery periods have been reported (Graziadei and Monti Graziadei,
1980; Costanzo et al., 2006). Early studies of NTx inserted a rigid steel blade between
the OB and cribriform plate to lesion sensory axons. Costanzo (1985) developed a new
technique that used a flexible Teflon blade to transect sensory axons, leading to
reduced injury to the cribriform plate and the surface of the OB. Neuronal regeneration
in the OB of mice is observed as early as day 15 following NTx with the Teflon blade
(Costanzo et al., 2006).

8

Regenerated axons reestablish functional synapses in the OB, as demonstrated
by both electrophysiological and behavioral experiments. In salamanders, electroolfactogram and extracellular unit activity recordings measured decreased sensory
neuronal activity 10 days following NTx, indicating OSN degeneration (Simmons and
Getchell, 1981a; Simmons and Getchell, 1981b). As early as 24 days after injury,
neuronal activity was observed and by day 100 returned to control levels, signifying
reinnervation of the OB. A similar response to electrical stimuli has been reported in
other species. Negative evoked potential studies measured activity in hamster OB as
early as day 20 following NTx and returned to control levels by day 30 (Koster and
Costanzo, 1996). This demonstrated that sensory neurons reestablished functional
synaptic connections with the dendrites of second order neurons.
Behavioral studies indicate that animals have the capacity to detect and
distinguish odors following nerve injury. Pigeons and goldfish detect odors within two
weeks following NTx (Oley et al., 1975; von Rekowski C. and Zippel, 1993). This
recovery period is more rapid than in mammals and is likely due to the more simple
anatomy of olfaction in lower species. The olfactory nerves in pigeons and goldfish form
a single nerve projection to the bulb, whereas in mammals, the organization is more
extensive. Yee and Costanzo (1995) reported that mice were able to detect odors within
40 days following NTx. However, the ability to discriminate individual odors was
impaired and mice required an additional learning period to distinguish odors (Yee and
Costanzo, 1995; Yee and Costanzo, 1998). This impaired discrimination may be related
to distortion of the topographical organization of the olfactory system following NTx.
Costanzo (2000) demonstrated that regenerated OSNs converge on multiple glomeruli
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in the OB after injury. Following olfactory injury, patients complain of pleasant odors
(e.g. flowers) taking on unpleasant qualities, such as rotting trash. Since the
topographical map is distorted, the glomerular activation by an odor is altered, and
therefore, the odor is misidentified by the olfactory cortex.
The morphological changes associated with NTX have been well studied, but
little is known about the molecular mechanisms responsible for the reinnervation of the
OB. Although the topographical map is maintained during normal turnover of OSNs, it
becomes distorted following injury. This suggests that injury-related changes in the OB
are responsible for the altered projections of sensory axons. Examining the processes
present in the OB following NTx can lead to a better understanding of how the olfactory
system responds to injury and may uncover novel therapeutic interventions aimed at
improving neuronal recovery.

1.2 Introduction to the matrix metalloproteinases
The matrix metalloproteinases (MMPs) are a family of enzymes important in the
remodeling of the extracellular matrix (ECM). Gross and Lapiere (1962) first described
MMP activity in tadpole tissue, later named MMP-1. The ability to modulate the ECM
has implicated MMPs in different physiological processes including development,
angiogenesis, and neuronal growth (Nagase and Woessner, Jr., 1999). To date, there
are 25 enzymes in the vertebrate MMP family divided into 6 categories (Table 1.1)
based on substrate specificity and structural properties (Sternlicht and Werb, 2001).
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1.2.1 MMP structure and domains
The structure of MMPs varies between categories, however most have 5 conserved
domains: prepro, pro, catalytic, hinge, and hemopexin-like. The preprodomain signals
the translocation of the MMP to the endoplasmic reticulum and is cleaved upon arrival
(Sternlicht and Werb, 2001). The prodomain maintains the enzyme as a zymogen, or
inactive enzyme. The interaction of a cysteine moiety in the prodomain with the catalytic
divalent cation renders the enzyme inactive. This interaction is called the cysteine
switch, and its disruption is necessary for enzyme activity (Becker et al., 1995; Nagase
et al., 1991; Springman et al., 1990). The catalytic domain contains the conserved
sequence HEXXHXXGXXHZ, in which the 3 histidines (H) anchor the catalytic Zn2+. The
Zinc moiety, bound to a water molecule, is polarized by the glutamyl carboxylate (E),
leading to nucleophilic attack on scissile peptide bonds (Stocker et al., 1995). Between
the catalytic and hemopexin-like domains is the hinge region, which stabilizes the
enzyme and assists in collagenolytic activity (Knauper et al., 1997). The C-terminal
hemopexin-like domain assists in recognition and cleavage of substrates (Patterson et
al., 2001). The endogenous inhibitors of MMPs, tissue inhibitor of metalloproteinase
(TIMPs), bind to and inactivate MMPs in this domain (Sternlicht and Werb, 2001).
The MMPs are a diverse family of enzymes, mainly due to their different
structures. Although most MMPs are secreted, there exists a membrane bound
category. The membrane-type matrix metalloproteinases (MT-MMP) have either a
single pass transmembrane domain (MMP-14, -15, -16, -24) or a C-terminal
glycophosphatidylinositol signal (MMP-17 and -25) that anchors the enzyme to the
membrane (Itoh et al., 1999; Kojima et al., 2000). MMP-9 and MMP-2 have a
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Table 1.1: The vertebral matrix metalloproteinases Table

Category

MMP

Common Name(s)

Collagenase

MMP-1
MMP-8
MMP-13
MMP-18

Collagenase-1
Collagenase-2
Collagenase-3
Collagenase-4 (Xenopus)

Gelatinase

MMP-2
MMP-9

Gelatinase A
Gelatinase B

Stromelysin

MMP-3
MMP-10
MMP-11
MMP-19

Stromelysin-1
Stromelysin-2
Stromelysin-3
RASI-1 (Stromelysin-4)

Matrilysin

MMP-7
MMP-26

Matrilysin-1
Matrilysin-2 (Endometase)

Membrane type

MMP-14
MMP-15
MMP-16
MMP-17
MMP-24
MMP-25

MT1-MMP
MT2-MMP
MT3-MMP
MT4-MMP
MT5-MMP
MT6-MMP

Other

MMP-12
MMP-20
MMP-21
MMP-22
MMP-23
MMP-27
MMP-28

Macrophage metalloelastase
Enamelysin
XMMP (Xenopus)
CMMP (chicken)
Cysteine-array MMP
Epilysin
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fibronectin type II domain insert in the catalytic region that assists in binding and
cleavage of substrates, while MMP-7, -23 and -26 lack a linker domain (Murphy and
Nagase, 2008; Steffensen et al., 1995). These structural differences allow for proteolytic
cleavage of a wide variety of substrates.

1.2.2 Activation of MMPs
Due to their potential destructive capability towards the ECM, MMPs are strictly
regulated at multiple levels. Most MMPs require transcriptional activation, which can be
induced by various molecules such as the inflammatory cytokines: TNF-α, IL-1β, and IL8 (Galis et al., 1994; Pugin et al., 1999). These cytokines activate intracellular cascades
that induce expression of various proteins, one of which is the transcriptional factor
activator protein-1 (AP-1). This molecule binds to specific regions of DNA to promote or
enhance transcription (Agrawal et al., 2008).
Another important level of regulation is disruption of the cysteine switch. There
are two ways to remove the cysteine switch: removal of the prodomain or Snitrosylation. Many enzymes have the ability to remove the prodomain to activate MMPs
including furin (Pei and Weiss, 1995; Pei and Weiss, 1996), plasmin (Carmeliet et al.,
1997), and other MMPs (Fridman et al., 1995; Ogata et al., 1992). A unique example of
prodomain removal is found in MMP-2 activation. Initially, MT1-MMP binds to TIMP-2,
forming a complex that binds a latent MMP-2 at the C-terminal domain (Strongin et al.,
1995; Sato et al., 1994). The MT1-MMP cleaves a fragment of the latent MMP-2
prodomain. The final step requires a previously activated MMP-2 to be recruited to the
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complex, which removes the remaining portion of the prodomain and activates the
enzyme (Deryugina et al., 2001).
Studies have shown that removal of the prodomain is not necessary for MMP
activation. The cysteine switch can be disrupted by S-nitrosylation in which a nitric oxide
(NO) molecule reacts with the inhibitory cysteine to form a cysteine derivative. This
derivative releases the catalytic Zn2+, rendering it available for proteolytic cleavage of
substrates (Van Wart and Birkedal-Hansen, 1990; Gu et al., 2002).
The activity of MMPs can be regulated by endogenous inhibitors called TIMPs.
These proteins bind to the C-terminus of MMPs, rendering the MMP inactive. Although
there exist only 4 TIMPs, each MMP is inhibited by at least one TIMP, forming a tight
1:1 complex (Nagase and Woessner, Jr., 1999).

1.2.3 MMPs in the normal CNS
In the developing and normal CNS, only a few MMPs are expressed and their
importance is not fully understood (Anthony et al., 1998). During development, MMP-9
plays an important role in neurite growth and the vascularization of the cortex (Canete
et al., 1995). Vaillant et al. (2003) reported that the granular layer of the cerebellum was
enlarged in MMP-9-/- mice. They concluded that MMP-9 assisted in the fine tuning of the
cerebellar neuronal networks by controlling granular cell apoptosis during development.
Several MMPs are important in the targeting of axons during development by degrading
axonal guidance molecules. This suggests that a balance between MMPs and guidance
cues are necessary for normal development (Galko and Tessier-Lavigne, 2000). During
learning and memory, MMP-3 and MMP-9 are localized to the hippocampus and are
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thought to have a role in synaptic remodeling to process the new information (Meighan
et al., 2006). MMP-9 and MMP-2 have been localized to microglia, astrocytes and
neurons in the normal CNS, but the importance of this observation remains unclear
(Cuzner et al., 1996; Anthony et al., 1997). Although more research is needed, MMPs
seem likely to have critical roles in the developing and normal CNS due to their ability to
remodel the ECM.

1.2.4 The role of MMPs in CNS injury and recovery
When mature CNS neurons are provided a peripheral nerve graft, they were
observed to grow long distances (Benfey and Aguayo, 1982; Huebner and Strittmatter,
2009). This suggests that CNS neurons retain the capacity to regenerate after
development. Therefore, injury-related changes to the ECM may be responsible for
limited CNS recovery. There are two classes of neuronal inhibitors in the CNS: myelinassociated inhibitors (MAIs) and chondroitin sulfate proteoglycans (CSPGs). Following
CNS injury, oligodendrocytes express MAIs that interact with Nogo-66 receptor on
neurons, attenuating the growth of axons (Huebner and Strittmatter, 2009). CSPGs are
a component of the astroglial scar and function to wall off the injured tissue, which
prevents secondary injury. However, CSPGs are also a physical barrier to neuronal
growth and may limit recovery in the CNS (Morgenstern et al., 2002). Studies showed
that MMPs are capable of proteolytic degradation of MAIs and CSPGs (Pizzi and
Crowe, 2007). This led researchers to focus on the role of MMPs in CNS injury and
recovery.

15

Interestingly, the gelatinases (MMP-9 and MMP-2) are temporally expressed in
many models of CNS injury including spinal cord injury (SCI), stroke, and multiple
sclerosis (Anthony et al., 1997; Noble et al., 2002; Rosenberg et al., 1996). Generally,
MMP-9 is increased immediately following injury, while MMP-2 expression is delayed for
up to a week. Although these two MMPs have a similar structure and substrate
specificity, the different temporal expression suggests MMP-9 and MMP-2 have
different roles in CNS injury and recovery. The immediate expression of MMP-9 is
associated with the early inflammatory response. Neutrophils, an inflammatory
leukocyte, release MMP-9 in both stroke and SCI, which may have a role in neutrophil
diapedesis and migration through the ECM (Justicia et al., 2003; de, Jr. et al., 2000;
Murphy et al., 1991). Later in neuronal recovery, macrophages gradually replace
neutrophils in the injured tissue. There are conflicting reports as to whether
macrophages contain MMP-9 (Fleming et al., 2006; Larsen et al., 2003; Anthony et al.,
1997). These different observations may be related to multiple factors including animal
species, injury model, and multiple phenotypes of macrophages.
The importance of MMP-9 in neuronal injury and recovery has been
demonstrated by targeted genetic disruption in mice. Following SCI, MMP-9-/- mice have
less disruption of the blood-spinal cord barrier, attenuated neutrophilic infiltration,
increased NG2 proteoglycan levels, and have increased functional recovery (Noble et
al., 2002). The latter observation suggests that MMP-9 may have a detrimental role in
CNS recovery. MMP-9 degrades both adhesion molecules important for neuron-ECM
interaction and components of myelin (Gijbels et al., 1993; Zalewska et al., 2002).
Proteolytic degradation of these neuronal components leads to nerve apoptosis.
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Therefore, MMP-9 may contribute to a secondary trauma by damaging neurons that
escaped the initial injury.
The importance of MMP-2 in CNS injury and recovery is not well understood. In
vitro, MMP-2 is secreted by the growth cones of neurites, while in vivo MMP-2 is
expressed in glial cells and neurons following nerve injury (Muir, 1994; Planas et al.,
2001; Zuo et al., 1998). MMP-2-/- mice have impaired functional recovery and increased
glial scar formation, suggesting that MMP-2 is important for neuronal recovery in the
CNS (Hsu et al., 2006). MMP-2 is thought to degrade CSPGs, allowing regenerated
neurons to pass through the glial scar and reestablish synaptic connections in the CNS.

1.3 Project goals, hypotheses, and specific aims
The goal of this research is to determine the importance of MMP-9 and MMP-2 in
olfactory injury and recovery. To accomplish this, 3 olfactory injury models will be
examined: 1) nerve transection (NTx), 2) methyl bromide gas (MeBr) exposure, and 3)
nerve transection with Teflon barrier (NTx-TB). These injury models produce varying
degrees of CNS trauma and neuronal recovery. Comparing the temporal expression of
MMP-9 and MMP-2 in each model will determine the importance of these MMPs in
olfactory injury and recovery processes. Previous studies have demonstrated that MMP9 has a role in the initial inflammatory response following CNS injury, while MMP-2 is
important for neuronal recovery (Noble et al., 2002; Rosenberg et al., 1996). Therefore,
it is hypothesized that MMP-9 will be associated with the inflammatory response
following olfactory injury, while MMP-2 will be important for neuronal recovery in the
OB.
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Hypothesis 1: MMP-9 and MMP-2 are increased at critical time periods in the OB
during neuronal degeneration and reinnervation following NTx.

Specific aim 1a: Determine the time course of neuronal degeneration and reinnervation
of the OB following NTx.
To establish the time course of neuronal degeneration and reinnervation
following NTx, changes in olfactory marker protein (OMP) expression, a marker for
mature sensory axons, will be measured by Western blot. A decrease in OMP will
indicate neuronal degeneration, and a subsequent increase in OMP will signify
reinnervation of the OB.

Specific aim 1b: Determine the temporal expression of MMP-9 and MMP-2 in the OB
following NTx.
The temporal expression of MMP-9 and MMP-2 following NTX will be measured
by Western blot. The changes in MMP levels will be compared with the neuronal
degeneration and reinnervation time course established in specific aim 1a. This will test
the hypothesis that MMP-9 and MMP-2 are associated with neuronal degeneration and
reinnervation of the OB.

Hypothesis 2: MMP-9 is associated with the inflammatory response in the OB
following NTx.
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Specific aim 2a: Determine the time course of inflammatory leukocyte infiltration into
the OB following NTx.
Inflammatory

leukocyte

infiltration

into

the

OB

will

be

monitored

by

immunohistochemistry at different recovery time points. Neutrophils will be identified
with myeloperoxidase (MPO), an enzyme that is stored in the azurophilic granules of
these cells (Klebanoff, 2005), while macrophages will be identified with CD68, a
glycoprotein expressed by this leukocyte.

Specific aim 2b: Localize MMP-9 to the inflammatory leukocytes
To determine if the inflammatory leukocytes contain MMP-9, colocalization
studies will be performed on the recovery days that correspond to leukocyte infiltration,
as determined in specific aim 2a. Colocalization of MMP-9 with the leukocyte markers
identified in specific aim 2a will test the hypothesis that neutrophils and macrophages
are a source of MMP-9 following NTx.

Hypothesis 3: MMP-9 is associated with neuronal degeneration

Specific aim 3a: Determine the time course of neuronal degeneration and reinnervation
of the OB following MeBr.
MeBr damages the cell bodies of sensory neurons in the OE, leading to neuronal
degeneration and subsequent reinnervation of the OB, without direct trauma to the CNS
(Schwob et al., 1995). To determine the time course of degeneration and reinnervation,

19

changes in OMP expression in the OB will be monitored by Western blot at different
time points following MeBr exposure.

Specific aim 3b: Determine the time course of MMP-9 in the OB following MeBr.
Changes in MMP-9 levels in the OB following MeBr will be measured by Western
blot. Comparing the temporal expression of MMP-9 with the neuronal degeneration
determined in specific aim 3a will test the hypothesis that MMP-9 is associated with
degeneration of sensory axons.

Specific aim 3c: Localize MMP-9 in the OB following MeBr.
Following MeBr, degradation of sensory axons should be evident in the nerve
and glomerular layers of the OB. Therefore, it is hypothesized that MMP-9 will be
localized in these layers. Immunohistochemical analysis of MMP-9 will be performed in
the OB at the time periods corresponding to neuronal degeneration, as established in
specific aim 3a.

Hypothesis 4: MMP-2 expression is associated with reinnervation of the OB

Specific aim 4a: Determine the expression of MMP-2 in the OB following NTx-TB.
MMP-2 has been reported to play an important role in neuronal recovery
following CNS injury (Rosenberg et al., 1996). To test the hypothesis that MMP-2 is
associated with reinnervation of the OB, a Teflon barrier will be inserted to block
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regenerated axons following NTx. Changes in MMP-2 expression will be measured by
Western blot at different recovery time points.

Specific aim 4b: Demonstrate blocking of regenerated axons with the Teflon barrier
following NTx.
The use of a Teflon barrier to block regenerated axons from reaching the bulb is
a novel model to study olfactory injury and recovery. The blockage of regenerated
axons by the barrier will be confirmed by histological analysis of the OB. Changes in
OMP, monitored by Western blot, will demonstrate the effect of the Teflon barrier on
reinnervation of the OB.

Successful completion of these specific aims will provide important information
regarding the roles of MMP-9 and MMP-2 in olfactory injury and recovery. In addition,
the comparison of 3 olfactory injury models represents a novel method to determine the
importance of specific molecular processes in CNS injury and recovery.
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Chapter 2
Expression of Matrix Metalloproteinase-9 and -2 Following Olfactory Nerve
Transection

2.1 Introduction
The olfactory system is a unique model for neurogenesis due to its remarkable
capacity to regenerate and replace neurons throughout life. Basal cells located in the
OE divide and differentiate into new neurons, replacing injured nerves over the course
of 30-45 days (Graziadei and Metcalf, 1971; Graziadei and DeHan, 1973; Graziadei and
Monti Graziadei, 1978; Hinds et al., 1984; Moulton, 1974). New neurons send axons to
the OB and establish functional synapses with second order neurons in structures
called glomeruli.
The projections of sensory axons to the bulb are highly organized, creating a
topographical map (Buck and Axel, 1991; Mombaerts et al., 1996; Ressler et al., 1994;
Vassar et al., 1993). Although the olfactory bulb contains over 1800 glomeruli (Royet et
al., 1988), subclasses of axons, based on the olfactory receptor expressed in the OE,
converge on only two specific glomeruli located on the medial and lateral aspects of the
bulb. This topographical organization is thought to have an important role in odor
discrimination and is maintained throughout normal turnover of neurons (Bozza and
Kauer, 1998; Mombaerts et al., 1996; Royet et al., 1988; Wang et al., 1998).
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Following injury, basal cells in the OE differentiate into new neurons, replacing
the injured OSNs. The time course of neuronal degeneration and recovery following
olfactory nerve injury has been established (Costanzo, 1985; Costanzo et al., 2006;
Graziadei and DeHan, 1973). The degeneration of sensory axons occurs during the first
two weeks, followed by the regenerative phase. New neurons send axons to the bulb
and reestablish functional synaptic connections with second order neurons by day 40
(Yee and Costanzo, 1995). However, the axons converge on multiple glomeruli,
distorting the topographical organization (Costanzo, 2000). The distortion of the
topographical map is likely due to injury-related processes because sensory axonal
projections to the OB are maintained during normal turnover. Although the
morphological changes associated with olfactory nerve injury is well characterized, little
is known about the molecular mechanisms important for neuronal regeneration and
reinnervation of the OB.
This study focuses on the expression of MMP-9 and MMP-2 in the OB following
NTx. These MMPs are important for degeneration and recovery processes in different
models of CNS injury. MMP-9 expression increased immediately following injury and
associated with the initial inflammatory response, glial scar formation, and blood-brain
barrier disruption (Gijbels et al., 1993; Larsen et al., 2003; Noble et al., 2002; Planas et
al., 2001; Rosenberg et al., 1996). In contrast, MMP-2 is often delayed for up to a week
after injury and correlates with the transition from neuronal degeneration to recovery
(Hsu et al., 2006; Rosenberg et al., 1996). MMP-2 is expressed in growth cone and cell
bodies of neurons, suggesting a role in neuronal regeneration and reinnervation (Muir,
1994; Planas et al., 2001).
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This chapter introduces the NTx as a model for neuronal injury and recovery, and
examines the response of MMP-2 and MMP-9 in the OB following NTx. It is
hypothesized that MMP-9 will increase immediately after NTx while MMP-2 expression
will be delayed, corresponding to critical periods of neuronal degeneration and recovery.
The goal of these experiments is to determine the temporal expression of MMP-9,
MMP-2, neuronal degeneration, and reinnervation of the OB following NTx .

2.2 Materials and Methods
Surgical procedure. Adult P2-IRES-tau-lacZ mice were anesthetized with
sodium pentobarbital (80 mg/kg, intraperitoneal). The P2 sensory neurons in these mice
express a tau-lacZ fusion protein that allows for observing axonal projections from the
OE to the OB. After anesthesia, the left OB was exposed and a thin, Teflon cutting
blade was inserted between the bulb and the cribriform plate. The use of a Teflon blade
resulted in transection of all the olfactory axons that connect to the left olfactory bulb
and minimal damage to the olfactory bulb and cribriform plate (Figure 2.1). The right
bulb was not transected and served as an internal control (CTRL) for histological
analysis. After transection, the skin incision was sutured, and each animal was
observed postoperatively before returning to its cage. All procedures were approved by
the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Tissue preparation for histology. Mice were anesthetized with sodium
pentobarbital and perfused transcardially with saline followed by 4% paraformaldehyde
(ICN Biomedicals, Inc., Aurora, OH). The skulls were removed and placed in 4%
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Figure 2.1: Diagram illustrating the NTx procedure and tissue collection for Western
blot analysis 2

Figure 2.1: Diagram illustrating the NTx procedure and tissue collection for Western
blot analysis. A. The Teflon blade is inserted between the CP and OB, leading to
complete transection of sensory axons. B. After different recovery time points, the OB is
cut (represented by the dotted line), and the anterior-ventral portion is collected. A:
anterior; CP: cribriform plate; G: glomerulus; OB: olfactory bulb; V: ventral.
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paraformaldehyde for 30 minutes, then rinsed with tap water for 5 minutes and
immersed in Decal overnight (Decal Chemical Corp, Tallman, NY). The following day,
skulls were placed in Invitrogen (Carlsbad, CA) phosphate-buffered saline (PBS)
containing 30% sucrose for a week, then frozen in a minus 80oC freezer. Horizontal
sections were cut on a Microm HM 550 series Cryostat (MICROM International GmbH,
Walldorf, Germany) and placed on Superfrost® Plus VWR® Micro Slides (VWR, West
Chester, Pennsylvania). The slides were stored in a minus 20oC freezer until processed.

Hematoxylin and eosin histology. Before processing, each slide was allowed
to reach room temperature and then washed with PBS for 10 minutes. Sections were
immersed for one minute intervals in a series of ethanol solutions (70%, 95%, 100%,
95%, 70%). Slides were placed in Harris Modified Hematoxylin (Fisher, Fair Lawn, NJ)
for 5 minutes, rinsed in running tap water for 3 minutes and then placed in a 1% acid
alcohol solution (1% hydrochloric acid in 70% alcohol) for 2 seconds. Following a 3
minute rinse in tap water, the sections were placed in an eosin solution (Fisher) for 5
minutes and rinsed for 5 minutes in running tap water. The slides were then mounted
with CryosealTM 60 (Richard-Allan Scientific, Kalamazoo, MI) and visualized on an
Eclipse E600 microscope (Nikon Inc, Melville, NY).

DAB immunohistochemistry. 3,3'-diaminobenzidine (DAB) staining for OMP
was performed on CTRL and day 60 transected bulbs to observe changes in glomerular
morphology following NTx. After washing with PBS for 10 minutes, sections were placed
in 0.01 M citric acid solution with steam for 10 minutes, followed by a wash in PBS for
10 minutes. Sections were then immersed for 1-minute intervals in a series of alcohol
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solutions (70%, 95%, 100%, 95%, and 70%) and placed in PBS wash for 5 minutes.
Nonspecific binding was blocked with solution containing 10% normal rabbit serum, 4%
bovine serum albumin, 5% nonfat dry milk, and 0.2% Triton X-100 in PBS for 1 hour.
The slides were then incubated with goat anti-OMP primary antibody (1:10; Wako
Chemicals, Richmond, VA) in the blocking solution overnight. The following day, the
slides were washed 3 times in PBS for 5 minutes then incubated in peroxidaseconjugated rabbit anti-goat IgG secondary antibody (1:50; Rockland Immunochemicals,
Inc., Gilbertsville, PA) in blocking solution, then exposed to DAB (Vector Laboratories,
Inc., Burlingame, CA). Sections were counterstained with Harris Modified Hematoxylin
(Fisher) and visualized on an Eclipse E600 microscope (Nikon, Inc., Melville, NY).

Western blot tissue sampling and preparation. Protein expression of MMP-9
and MMP-2 was measured by Western blot analysis. At 5 hours and 1, 3, 7, 10, 15, 35
and 60 days after the NTx, mice were anesthetized with sodium pentobarbital and killed
by rapid decapitation. The left olfactory bulb tissue was carefully removed along with left
bulb tissue from CTRL animals (receiving no surgical treatment). Although the right bulb
of transected mice serves as an internal CTRL, occasionally some injury is observed in
this bulb. Therefore, CTRL animals were used to ensure that no injury was present in
CTRL samples. The left bulbs were immediately placed in protein extraction buffer (50
mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium dodecylsulfate [SDS], 1% DOC)
and homogenized with a motor-driven plastic homogenizer. The tissue was incubated
on a rotating platform for 20 minutes at 4°C and centrifuged at 16,000g for 30 minutes
at 4°C. Solubilized proteins in the supernatant were quantified with a DC protein assay
reagent kit (Bio-Rad Laboratories, Hercules, CA), using bovine serum albumin as a
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standard. Protein measurements were made at 720 nm on a μQuant plate reader
(BioTek Instruments Inc., Winooski, VT). Equal protein samples and purified murine
MMP-9 or MMP-2 (Chemicon, San Francisco, CA) were loaded onto Bis-Tris 4–12%
density gradient gels and separated using NuPAGE MES [2-(N-morpholino) ethane
sulfonic acid] reducing buffer system (Invitrogen) for 1 hour at 200 V and 4°C. Protein
was transferred to nitrocellulose membranes for 2 hours at 25 V and 4°C. Nonspecific
binding was blocked with 5% bovine nonfat dry milk in Tris-buffered saline and 0.05%
Tween-20 for 1 hour. Goat anti-MMP-9 and goat anti-MMP-2 primary antibodies (1:200)
were obtained from R&D Systems (Minneapolis, MN). Goat anti-OMP (1:20,000; Wako
Chemicals) was used as a marker of axonal degeneration and regeneration in the bulb.
Rabbit anti-cyclophilin A (CPA) (1:5000; Upstate, Lake Placid, NY) antibody was used
to standardize protein loading. Nitrocellulose membranes were incubated overnight in
primary antibody at 4°C. Membranes were then treated with species-specific
peroxidase-conjugated IgG secondary antibodies (Rockland Immunochemicals, Inc.) for
1 hour, then incubated for 1 minute with Western Lightning Plus reagent (Perkin Elmer,
Wellesley, MA) and exposed to Blue Sensitive Autoradiography film (Marsh
BioProducts, Rochester, NY).

Protein measurement. Quantification of protein expression was performed
using Quantity One Analysis software (Bio-Rad Laboratories). Protein expression was
measured as a function of both band density and band area. This density–area
measurement for MMP-9, MMP-2, and OMP at each recovery time point was then
standardized against the corresponding density–area measurement for CPA in the
same gel. The protein measurement of MMP-9, MMP-2, or OMP was then expressed as
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a ratio of CPA (amount of protein divided by amount of CPA) and normalized to CTRL
levels (amount of protein/CPA ratio divided by amount of CTRL protein/CPA ratio).
Gelatin zymography. MMP-9 activity was measured by gelatin zymography.
Purified murine MMP-9 and equal amounts of protein from each recovery period (5
hour, 1, 3, 7, 10, 15, 35, and 60 days) were loaded onto a 10% zymogram (gelatin) gel
(Invitrogen) and separated using Novex Tris-glycine SDS buffering system (Invitrogen)
for 3 hours at 135 V and 4°C. The gel was then incubated in Novex Zymogram
Renaturing Buffer (Invitrogen) for 1 hour and transferred to developing buffer (0.5%
coommassie blue, 10% acetic acid, 10% ethanol) for 24 hours at 37°C. The following
day, the gels were placed in a destaining buffer (10% acetic acid, 10% ethanol) for 1
hour and visualized on a light box. Images were captured with a Nikon D60 camera.
Statistical analysis. Protein levels at each of the Western blot recovery time
points were compared to CTRL values using 2-way ANOVA and a Holm-Sidak 2-sided
post hoc test. A probability of less than 0.05 was considered statistically significant. All
statistical analysis was performed using SPSS software (IBM, Chicago, IL).

2.3 Results
Neuronal recovery following NTx. The normal olfactory bulb has 6 distinct
morphological layers: nerve, glomerular, external plexiform, mitral, internal plexiform,
and granule cell (Figure 2.2A). Sensory axons from the epithelium passed through the
cribriform plate to the nerve layer and terminated in the glomerular layer. The day 1 NTx
bulb showed disruption of the nerve, glomerular, and anterior portion of the external
plexiform layers, while the deeper layers and posterior bulb remained intact (Figure

30

Figure 2.2: Comparison of the OB from CTRL and NTx mice3

Figure 2.2: Comparison of the OB from CTRL and NTx mice. A. The six distinct
morphological layers are evident in CTRL bulbs. Sensory axons (arrows) from the OE
pass through the CP to the outer NL, terminating on the GL. B. Following NTx, the NL,
GL and anterior EPL are disrupted (asterisk), leaving the deeper layers (ML, IPL, and
GCL) and posterior bulb intact. This indicates that the transection procedure selectively
cuts the sensory axons. The corresponding CTRL bulb remains relatively intact,
however injury is occasionally seen. In this bulb, injured tissue is limited to the anterior
NL (arrowhead). CP: cribriform plate; CTRL: control; EPL: external plexiform layer;
GCL: granule cell layer; GL: glomerular layer; IPL: internal plexiform layer; ML: mitral
layer; NL: nerve layer; NTx: nerve transection; OB: olfactory bulb; OE: olfactory
epithelium. Scale bars: 500 μm.
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Figure 2.3: Injury-related changes in OMP expression in the OB following NTx4

Figure 2.3: Injury-related changes in OMP expression in the OB following NTx. A.
Representative Western blot measuring OMP expression at different recovery time
points. Lane 1 represents OMP levels in untreated, control mice. CPA levels serve as
gel loading control. B. Plot of the mean OMP expression, normalized to CTRL levels,
from four separate Western blots. OMP remained near CTRL expression 5 hours
following NTx. By day 1, OMP expression decreased and reached a minimum by day
10. This represents the degeneration of sensory axons in the OB. Between days 10 and
15, OMP increased to CTRL levels, which indicates reinnervation of the OB, and
remained elevated through day 60. Data points represent the mean ± SEM (n=4 at each
time point). ANOVA analysis with a Holm-Sidak post hoc for each time point compared
to CTRL is given in Table 2.1. CPA: cyclophilin A; CTRL: control; NTx: nerve
transection; OMP: olfactory marker protein.
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Figure 2.4: Changes in P2 odorant receptor projections following NTx5

Figure 2.4: Changes in P2 odorant receptor projections following NTx. Whole mount
preparations showing the medial aspect of the OB and OE. P2 axons (dark blue) project
from the OE to the OB, converging on two discrete loci called glomeruli (arrows).
Several days following NTx, sensory axons degenerate and are not apparent in the bulb
(day 7). Some faint staining is evident in the OE, although it is unclear if these neurons
are degenerating or newly regenerated. After long recovery periods (days 35 and 60),
regenerated sensory neurons are observed in the OE and OB. However, the axons
converge on three or four glomeruli (arrows), indicating an altered projection of P2
axons to the OB. NTx: nerve transection; OB: olfactory bulb; OE: olfactory epithelium.
Scale bars: 1 mm.
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Figure 2.5: OMP expression in CTRL and NTx bulbs demonstrating changes in
glomerular morphology6

Figure 2.5: OMP expression in CTRL and NTx bulbs demonstrating changes in
glomerular morphology. A. Low power image showing the CTRL and day 60 NTx bulbs.
OMP positive axons (brown) project to the outer NL and terminate in the GL. B. High
power image illustrating the normal morphology of glomeruli, having a homogenous,
spherical appearance (asterisk). C. Following neuronal reinnervation of the OB,
glomeruli are punctated and have a heterogeneous appearance (arrowheads). Asterisk
and arrows in A correspond to glomeruli in B and C. CTRL: control; GL: glomerular
layer; NL: nerve layer; NTx: nerve transection; OMP: olfactory marker protein. Scale
bars: A: 500 μm; B&C: 100 μm.

37

38

2.2B). This indicated that the NTx selectively transected olfactory sensory axons while
minimizing damage to the bulb. The corresponding right bulb at day 1 is not transected
and serves as an internal CTRL, however some injury was occasionally seen along the
nerve layer. To establish the time course of neuronal degeneration and reinnervation of
the OB, OMP, expressed by mature sensory axons, was monitored by Western blot
analysis (Figure 2.3A). The relative amounts of OMP expression are plotted in Figure
2.3B. OMP levels decreased at day 1 and remained below CTRL levels for two weeks,
indicating neuronal degeneration. Between days 10 and 15, OMP returned back to
CTRL, signifying reinnervation of the OB by regenerated sensory axons. The changes
in OMP expression demonstrated that the degeneration of sensory axons was observed
during the first two weeks following NTx, while reinnervation of the OB is apparent by
day 15.
Although reinnervation of the OB is observed following NTx, the projection of
sensory axons are distorted (Figure 2.4). In CTRL mice, P2 receptor axons originate in
the OE and converge on two discrete loci in the OB, called glomeruli. After NTx, the
sensory axons are completed degenerated in the bulb by day 7. Some dark blue
staining is evident in the OE, although it is unclear if these neurons are degenerating or
newly regenerated. Following long recovery periods (days 35 and 60), regenerated P2
axons project from the OE to the OB and converged on multiple glomeruli. This
demonstrated that the topographical map is distorted following recovery from NTx. OMP
histological analysis of day 60 transected mice showed altered glomerular morphology
in the NTx bulb compared to the corresponding internal CTRL bulb (Figure 2.5). The
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CTRL glomeruli had a uniform, spherical pattern (Figure 2.5B), while glomeruli in the
injured bulb were punctuated and vary in size (Figure 2.5C).
Matrix metalloproteinase expression after NTx. The changes in MMP-9 and
MMP-2 were measured at different recovery time periods that reflect neuronal
degeneration and reinnervation of the OB. Figure 2.6A shows a representative Western
blot illustrating the change in MMP-9 levels following NTx. CTRL bulbs did not have
detectable MMP-9. The relative amounts of MMP-9 at the different recovery time points
are plotted in Figure 2.6B. MMP-9 increased by 5 hours after injury, and its levels
peaked at day 1. The elevation of MMP-9 was observed for two weeks following NTx.
By day 15, MMP-9 started to decrease and returned to CTRL levels by day 60. The time
course of increased MMP-9 corresponded to decreased OMP expression (Figure 2.3).
As OMP increased at day 15, MMP-9 levels decreased. This suggests a correlation
between MMP-9 and degeneration of sensory axons. The antibody used in the Western
blot analysis was unable to detect the active form of MMP-9. Therefore, gelatin
zymography was performed to determine MMP-9 activity (Figure 2.7). The band
corresponding to the active form of MMP-9 was observed during the first two weeks of
injury (days 1-10), although a band at day 15 was seen in gel 3. This demonstrates that
MMP-9 is active during the first two weeks following NTx.
Western blot analysis of MMP-2 levels in the OB following NTx is shown in
Figure 2.8A. In CTRL bulbs, MMP-2 was detectable, confirming previous reports that
MMP-2 is constitutively expressed in the CNS (Anthony et al., 1997; Cuzner et al.,
1996). The relative amounts of MMP-2 at different recovery days are plotted in Figure
2.8B. Shortly after injury (5 hours), there was an injury-related increase in MMP-2 that
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Figure 2.6: Changes in MMP-9 expression in the OB following NTx7

Figure 2.6: Changes in MMP-9 expression in the OB following NTx. A. Representative
Western blot demonstrating changes in MMP-9 after injury. Lane 1 contains purified
murine MMP-9. CTRL bulbs have no detectable MMP-9. CPA levels serve as gel
loading control. B. Plot of the mean MMP-9 expression, normalized to CTRL levels,
from four separate Western blots. MMP-9 expression was increased 5 hours following
injury. The levels peaked at day 1 and remained elevated through day 10. At day 15,
MMP-9 expression decreased and returned to CTRL levels by day 60. Data point
represent mean ± SEM (n=4 at each time point). ANOVA analysis with a Holm-Sidak
post hoc for each time point compared to CTRL is given in Table 2.1. CPA: cyclophilin
A; CTRL: control; OB: olfactory bulb.
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Figure 2.7: Gelatin zymography illustrating changes in the pro and active forms of
MMP-9 following NTx8

Figure 2.7: Gelatin zymography illustrating changes in the pro and active forms of
MMP-9 following NTx. A. 3 zymography gels show the band corresponding to the active
form of MMP-9 between days 1 and 10 following NTx. An active MMP-9 band is
observed at day 15 in the lower gel (3). B. Table summarizing changes in the active
form of MMP-9 following NTx. +: active MMP-9 observed; Ø: no active form of MMP-9
detected. NTx: nerve transection.
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Figure 2.8: Changes in MMP-2 levels in the OB following NTx9

Figure 2.8: Changes in MMP-2 levels in the OB following NTx. A. Representative
Western blot demonstrating MMP-2 expression at different recovery time points. Lane 1
contains purified murine MMP-2. CTRL mice (lane 2) have detectable levels of MMP-2.
CPA levels serve as gel loading control. B. Plot of the mean expression of MMP-2,
normalized to CTRL levels, from four separate Western blots. A 5-fold increase in MMP2 was detected within 5 hours after injury and remained at this level for the first few
days. At day 7, MMP-2 expression rapidly increased and peaked at 11.5-fold above
CTRL levels. By day 10, MMP-2 decreased back to the day 3 levels and returned to
CTRL at day 35. Data points represent the mean ± SEM (n=4 at each time point).
ANOVA analysis with a Holm-Sidak post hoc for each time point compared to CTRL is
given in Table 2.1. CPA: cyclophilin A; CTRL: control; NTx: nerve transection; OB:
olfactory bulb.
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Table 2.1: Table summarizing the significant Western blot recovery points compared to
CTRL for OMP, MMP-9, and MMP-2 Table

Recovery

OMP
p

MMP-9
p

MMP-2
p

5H

0.598

0.207

0.038

D1

0.073

<0.001

D3

0.087

<0.001

D7

0.016

D10

0.014

D15

0.755

0.058

0.002

D35

0.964

0.515

0.948

D60

0.912

0.883

0.653

*
*

0.001
<0.001

**
**
**
**

*: p<0.05; **: p<0.01
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*

0.065
<0.001
<0.001

**
**

0.215

**

was sustained for the first few days following NTx. However, between days 3 and 7,
MMP-2 increased rapidly and peaked at 11.5 fold higher than CTRL levels. By day 10,
MMP-2 decreased back to the day 3 levels and returned to CTRL at day 35.
Table 2.1 shows 2-way ANOVA and Holm-Sidak post-hoc analysis demonstrating the
Western blot recovery time points that are significant compared to CTRL levels for
OMP, MMP-9, and MMP-2 expression.

2.4 Discussion
This report demonstrated the temporal expression of MMP-9 and MMP-2
following NTx. MMP-9 increased rapidly after injury and remained elevated for up to two
weeks. This time period corresponded to the degeneration of sensory axons. A peak in
MMP-2 expression was observed at day 7 and may correlate with the transition
between neuronal degeneration and reinnervation of the OB.
MMP-9 expression following NTx. MMP-9 has been shown to play an
important role in CNS injury-related processes such as gliosis, inflammation, and
degradation of neurons. In NTx, reactive gliosis is observed in the bulb during the first
few days after injury and remained elevated for over two months (Costanzo et al.,
2006). Gliosis is initiated by reactive astrocytes, the resident glial cells of the CNS.
Astrocytes have many important roles after injury including phagocytosis of neuronal
debris and formation of the glial scar (Kimelberg, 2010; Stichel and Muller, 1998).
Specifically, the glial scar has dichotomous roles in neuronal injury and recovery. It
functions to isolate the injured areas and prevent secondary trauma to the surrounding
tissue. However, components of the scar are inhibitory to neuronal growth including
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chondroitin proteoglycans (Morgenstern et al., 2002). Although olfactory sensory
neurons regenerate, the new axons converge onto multiple glomeruli in the bulb,
distorting the topographical map (Figure 2.4). In contrast, normal turnover of sensory
neurons maintains this map. This suggests that injury-related processes, such as the
glial scar, may play an important role in distortion of the topographical map.
During the immediate period following NTx, MMP-9 increased rapidly and peaked
by day 1 (Figure 2.6). The early expression of MMP-9 precedes the reported rise in
reactive gliosis in the OB after NTx. MMP-9 degrades components of the glial scar,
including CSPGs and may limit the extent of scarring (Hsu et al., 2008). Larsen et al.
(2003) demonstrated that MMP-9-/- mice have increased glial scarring following CNS
demyelination injury, demonstrating that MMP-9 may regulate glial scar formation.
Although this implies that MMP-9 serves a beneficial role in neuronal recovery, others
report that MMP-9-/- mice have improved functional outcomes following stroke and SCI
(Lee et al., 2004; Noble et al., 2002). These studies indicate that although MMP-9 has
multiple roles after injury, it may have an overall detrimental role in neuronal recovery.
The time course of MMP-9 elevation correlates with decreased OMP expression,
suggesting that MMP-9 may play a role in neuronal degeneration. MMP-9 degrades
components of myelin and adhesion molecules important for neuron-ECM interaction,
leading to neuronal apoptosis (Gijbels et al., 1993; Zalewska et al., 2002). The
expression of MMP-9 following injury may lead to indiscriminate proteolytic degradation
of both injured and the surrounding healthy neurons. Newman et al. (2001)
demonstrated that the injection of exogenous MMP-9 leads to neuronal injury, indicating
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that MMP-9 is detrimental to neurons. This may explain the observation that MMP-9KO
mice have improved neuronal recovery in CNS injuries.
One source of MMP-9 following CNS injuries is the inflammatory leukocytes,
neutrophils and macrophages (Fleming et al., 2006; Justicia et al., 2003; Noble et al.,
2002). The early rise in MMP-9 following NTx corresponded to the reported time course
of neutrophils infiltration in other CNS injuries (Carlson et al., 1998; Dusart and Schwab,
1994). During later stages of recovery, macrophages gradually replace neutrophils in
the injured tissue and are reported to contain MMP-9 (Larsen et al., 2003). The
immediate increase in MMP-9 following NTx may represent inflammatory leukocytes
recruitment in the OB, but the inflammation response following NTx has not been
studied.
MMP-2 expression following NTx. MMP-2 was measured in CTRL bulbs,
confirming previous reports that this protein in constitutively expressed in the CNS
(Anthony et al., 1997; Cuzner et al., 1996). Following NTx, MMP-2 expression increased
above CTRL and may indicate immediate injury-related changes in the OB (Figure 2.8).
The peak expression of MMP-2 observed at day 7 may signal the transition between
neuronal degeneration and reinnervation of the OB. Mature regenerated axons
expressing OMP were measured in the bulb between days 10 and 15. However, the
transition between immature and mature axons, and therefore, the expression of OMP
may take up to a week (Miragall and Monti Graziadei, 1982). This indicates that
immature axons may initially contact the bulb at day 7, leading to the peak expression of
MMP-2. MMP-2 is important for neuronal recovery, as MMP-2-/- mice have impaired
functional recovery following SCI (Hsu et al., 2006). Future studies are needed to
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determine the source of MMP-2 in the OB, which will determine, in part, the role of
MMP-2 in olfactory injury and recovery.
Conclusion. The results from the NTx experiments demonstrate a temporal
expression of MMP-9 and MMP-2 at critical periods during neuronal degeneration and
reinnervation of the OB. MMP-9 was expressed immediately following injury and
remained elevated for two weeks. This period corresponded to the degeneration of
sensory axons. MMP-2 levels initially increased following NTx, with a large peak
observed at day 7. This peak may correlate to the transition between neuronal
degeneration and reinnervation of the OB. Future studies aimed at targeted disruption
of MMP-9 and MMP-2 can determine the importance of these MMPs in olfactory injury
and may uncover novel therapeutic options to improve neuronal recovery.
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Chapter 3
MMP-9 is Associated with the Acute Inflammatory Response Following Olfactory
Nerve Transection

3.1 Introduction
The matrix metalloproteinases (MMPs) are a family of proteinases important in
the regulation of the extracellular matrix (ECM). These enzymes have the capacity to
degrade many prominent components of the matrix and play critical roles in
development, angiogenesis, and cellular migration (Canete et al., 1995; Itoh, 2006;
Zhou et al., 2000). However, if left unregulated, MMPs have the potential to promote
widespread tissue damage. Uncontrolled MMP activity initiates or exacerbates
pathological processes such as rheumatoid arthritis, metastatic cancer, and multiple
sclerosis (Gijbels et al., 1993; Melchiori et al., 1992; Brinckerhoff, 1991). In the CNS, a
category of MMPs, the gelatinases (MMP-9 and MMP-2) are frequently reported to have
increased temporal expression following different models of injury. MMP-2 is
constitutively expressed in the CNS and is increased following injury, although its
importance is not fully known (Rosenberg et al., 1996; Planas et al., 2001). MMP-9 is
immediately elevated following SCI, stroke, and traumatic brain injuries and is
associated with the initial inflammatory response (Hayashi et al., 2009; Justicia et al.,
2003; Noble et al., 2002).
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We have previously reported the expression of MMP-9 following olfactory NTx.
The olfactory system is a unique model for neurogenesis due to its capacity for neuronal
regeneration throughout life and following injury. Basal cells located in the epithelium
replace injured neurons and reestablish synaptic connections in the CNS. The time
course of neuronal degeneration and recovery following NTx has been previously
reported (Costanzo et al., 2006). Degeneration of sensory axons occurs during the first
two weeks, followed by neuronal recovery and establishment of functional synaptic
connections in the OB by day 40 (Yee and Costanzo, 1995). MMP-9 expression
increased rapidly after NTx and remained elevated for two weeks, corresponding to
neuronal degeneration and glial scar formation (Costanzo et al., 2006). As regenerated
axons contacted the bulb, MMP-9 levels decreased, suggesting this protein plays an
important role during acute injury events following NTx.
Although the time course of MMP-9 expression following NTx has been defined,
little is known about its role in olfactory neuronal degeneration and reinnervation of the
OB. In this study, we examine the cellular source of MMP-9 expression after injury.
Given previous reports that MMP-9 is involved in the acute inflammatory response
following different CNS injuries, we hypothesize that MMP-9 will be localized to
inflammatory leukocytes during the first two weeks following NTx. In addition, this report
will provide the first look at the inflammatory response in the OB after nerve injury.

3.2 Material and Methods
Surgical procedures. Adult P2-IRES-tau-lacZ mice were anesthetized with
sodium pentobarbital (80 mg/kg, intraperitoneal). After anesthesia, the left OB was
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exposed and a thin, Teflon cutting blade was inserted between the left bulb and the
cribriform plate. The use of a Teflon blade resulted in transection of all the olfactory
axons that connect to the left bulb with minimal damage to the bulb and cribriform plate.
The right bulb was not transected and served as an internal control (CTRL) for
histological analysis. After transection, the skin incision was sutured and each animal
was observed postoperatively before returning to its cage. All procedures were
approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University.
Immunohistochemistry.

Immunohistochemical

staining

for

MMP-9

and

myeloperoxidase (MPO) was performed at different recovery points following NTx: 1, 7,
10, and 60 days. CD68 labeling was performed on CTRL and days 1, 3, 7, 10, 15 and
60 NTx bulbs. Mice were anesthetized with sodium pentobarbital and perfused with
saline, followed by 4% paraformaldehyde (ICN Biomedicals, Inc., Aurora, OH). The
skulls were removed and placed in 4% paraformaldehyde for 30 minutes, rinsed with
tap water for 5 minutes, followed by immersion in either Decal (Decal Chemical Corp,
Tallman, NY) overnight or 0.3% ethylenediaminetetraacetic acid (EDTA) for a week.
Decal interfered with the 4,6-diamidino-2-phenylindole (DAPI) signal, and therefore,
DAPI staining was performed on skulls decalcified with EDTA. After decalcification,
skulls were placed in Invitrogen (Carlsbad, CA) phosphate-buffered saline (PBS)
containing 30% sucrose for a week, then frozen in a minus 80oC freezer. Horizontal
sections were cut on a Microm HM 550 series Cryostat (MICROM International GmbH,
Walldorf, Germany) and placed on Superfrost® Plus VWR® Micro Slides (VWR, West
Chester, Pennsylvania). The slides were stored in a minus 20oC freezer until processed.
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Before processing, each slide was allowed to reach room temperature, then
washed with PBS for 10 minutes. Microwave antigen retrieval was performed as
previously described with some modifications (Stone et al., 1999). Sections were heated
to 65oC for 8 minutes and allowed to cool for 20 minutes at room temperature. Following
antigen retrieval, slides were washed 3 times in PBS, then incubated for 1 hour in a
blocking solution containing 10% normal donkey serum (Jackson ImmunoResearch
Laboratories Inc., West Grove, PA) and 0.2% Triton X-100 (LabChem Inc. Pittsburgh,
PA) in PBS. The sections were then placed in blocking solution containing primary
antibodies overnight: goat anti-MMP-9 (1:10: R & D Systems, Minneapolis, MN), and
rabbit anti-MPO (MPO; 1:10; Abcam, Cambridge, MA), or goat anti-MMP-9 (R & D
Systems) and rat anti-CD-68 (1:100; AbD SeroTec, Raleigh, NC). The following day the
slides were washed 3 times in PBS and placed in the species appropriate donkey
secondary antibody. MMP-9 was incubated with CY3 conjugated donkey anti-goat
secondary antibody (1:300; Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA) while MPO and CD-68 were incubated with AlexaFluor 488 conjugated donkey antispecies appropriate secondary antibodies (1:100; Invitrogen) for 1 hour. The slides were
mounted using Vector mounting media containing DAPI (Vector Laboratories Inc.,
Burlingame, CA) and visualized on a Leica TCS-SP2 AOBS confocal microscope (Leica
Microsystems, Inc., Bannockburn, IL).
DAB immunohistochemistry. 3,3’-diaminobenzidine (DAB) staining for MMP-9
was performed on day 1 NTx bulbs. Tissue processing was identical to the
immunohistochemical protocol until the blocking step. Sections were blocked for 1 hour
in a solution containing 10% normal rabbit serum, 4% bovine serum albumin, and 5%
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nonfat dry milk in PBS. The sections were then incubated in goat anti-MMP-9 (1:10, R &
D Systems) primary antibody in block solution overnight. The following day, the slides
were washed 3 times in PBS and placed in peroxidase conjugated rabbit anti-goat
secondary antibody (1:50, Rockland Immunochemicals Inc., Gilbertsville, PA) for 1 hour.
The slides were washed 3 times in PBS, exposed to DAB (Vector Laboratories, Inc.)
and visualized on an Eclipse E600 microscope (Nikon Inc., Melville, NY).

3.3 Results
MMP-9 immunohistochemical staining at 4 recovery time points (days 1, 7, 10,
and 60) following NTx is shown in Figure 3.1. MMP-9 was apparent during the acute
period following injury (days 1, 7 and 10) only in the NTx bulb. The corresponding CTRL
bulbs at each time point did not contain MMP-9.

This suggests that MMP-9 is

associated with an injury-related process. By day 60, MMP-9 staining was not observed
in either the CTRL or NTx bulb.
To

determine

the

source

of

MMP-9,

co-localization

of

MMP-9

and

myeloperoxidase (MPO), a marker predominately for neutrophils, was performed
(Figure 3.2). At 3 recovery days (1, 7, and 10), MPO and MMP-9 signals were apparent
in the same cell. Nuclear staining with DAPI demonstrated that these cells have a
polymorphic nuclear morphology, which is characteristic of neutrophils. DAB staining on
day 1 bulbs further indicated that MMP-9 was localized to neutrophils, having the
characteristic polymorphic nucleus (Figure 3.3). Taken together, this strongly suggests
that neutrophils are the source of MMP-9 during the acute period following NTx.
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To determine if macrophages, another inflammatory leukocyte, are present in the
injured bulb following NTx, CD68 localization was monitored by immunohistochemistry.
The infiltration of CD68 positive cells, associated with the phagocytic phenotype of
macrophages (Micklem et al., 1989; Ramprasad et al., 1996), at different recovery time
points is shown in Figure 3.4. CD68 positive cells were not evident in the CTRL or day 1
OB. By day 3, CD68 positive cells were increased in the NTx bulb while absent in the
corresponding CTRL bulb. CD68 cells remained in the transected bulb at days 7 and
10, while absent in the CTRL bulbs. This indicates that macrophages are associated
with an injury-related response. Colocalization studies at three recovery days (7, 10,
and 15), when CD68 levels were maximal, show that CD68 positive macrophages do
not contain MMP-9 (Figure 3.5). Nuclear staining with DAPI demonstrated the cells that
contain MMP-9 are neutrophils, having the characteristic polymorphic nuclear
morphology.
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Figure 3.1: MMP-9 is localized only to the NTx bulb10
Figure 3.1: MMP-9 is localized only to the NTx bulb. At days 1, 7, and 10, MMP-9
(arrows) is evident in the NTx bulb, while no labeling is apparent in the corresponding
CTRL bulb. This suggests that MMP-9 is associated with the NTx injury. By day 60,
MMP-9 expression is not observed in either the CTRL or NTx bulb. CTRL: control; NTx:
nerve transection. Scale bar: 100 μm.
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Figure 3.2: Colocalization of MMP-9 with neutrophilic makers in the OB following NTx11

Figure 3.2: Colocalization of MMP-9 with neutrophilic makers in the OB following NTx.
Representative images from three recovery days (1, 7, 10) demonstrate that MPO
(green), a marker for neutrophils, and MMP-9 (red) are localized to the same cell
(yellow). Nuclear staining with DAPI demonstrates that the MPO/MMP-9 positive cells
have a polymorphic nucleus, the characteristic nuclear morphology of neutrophils.
Taken together, this indicates that neutrophils are a source of MMP-9 expression at
these three recovery days. However, some neutrophils do not contain MMP-9
(asterisks). DAPI: 4',6-diamidino-2-phenylindole; MPO: myeloperoxidase; NTx: nerve
transection. Scale bar for all images: 10 μm.
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Figure 3.3: DAB and hematoxylin staining demonstrates that neutrophils contain MMP9 in the OB following NTx12

Figure 3.3: DAB and hematoxylin staining demonstrates that neutrophils contain MMP9 in the OB following NTx. A. Low power images of the day 1 NTx bulb show disruption
of the normal morphology of the OB. MMP-9 positive cells (brown) are distributed
throughout the injured tissue (arrows). B. High power images confirm that the cells
expressing MMP-9 are neutrophils, having the characteristic polymorphic nuclei. Arrows
in (A) correspond to cells shown in (B). DAB: 3,3’-diaminobenzidine; NTx: nerve
transection; OB: olfactory bulb. Scale bars: A: 50 μm; B: 10 μm.
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Figure 3.4: Injury related changes in CD68 positive cells following NTx13

Figure 3.4: Injury related changes in CD68 positive cells following NTx. In CTRL and
day 1 NTx bulbs, CD68 cells, mainly associated with macrophages, are not evident. At
day 3, CD68 positive cells (arrows) are observed in the NTx bulb while absent in the
corresponding CTRL bulb. The day 7 and 10 images demonstrate CD68 cells remained
localized to the NTx bulb. This suggests that CD68 cells are associated with an injuryrelated response. By day 60, CD68 cells are not observed in the CTRL or NTx bulbs.
CTRL: control; NTx: nerve transection. Scale bar: 100 μm.

64

65

Figure 3.5: CD68 positive cells do not contain MMP-9 following NTx14

Figure 3.5: CD68 positive cells do not contain MMP-9 following NTx. Three
representative images at different recovery days (7, 10, 15) demonstrate that CD68
positive cells (green), associated mainly with macrophages, fail to co-localize with
MMP-9 (red). This indicates that CD68 positive cells do not contain MMP-9 in the bulb
following NTx. Nuclear staining with DAPI indicates that the MMP-9 positive cells have
polymorphic nuclei, indicating these cells are neutrophils. DAPI: 4',6-diamidino-2phenylindole; NTx: nerve transection. Scale bar for all images: 10 μm.
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3.4 Discussion
This study demonstrated that MMP-9 is localized to neutrophils in the injured
bulb during the acute period (days 1-15) following NTx. CD68 positive cells, a marker
for phagocytic macrophages, infiltrated the bulb by day 3 and remained elevated
through day 15. These cells do not contain MMP-9, suggesting that neutrophils are the
main source of MMP-9 in the OB following NTx.
Inflammation in the CNS. Barker and Billingham proposed that the CNS was an
immune privileged site and protected from inflammation following injury (Scholz et al.,
2007). One reason for this designation is the blood-brain barrier (BBB) prevents
trafficking of molecules between the vasculature and CNS. Transcellular transport is
inhibited because endothelial cells of the BBB have decreased pinocytosis and the BBB
lacks fenestrations (Mooradian, 1988). In addition, the endothelial cells are connected
together by adherens and tight junctions, preventing paracellular transport of molecules
(Pun et al., 2009). These characteristics of the BBB were thought to prevent
inflammatory cytokines from recruiting leukocytes to the CNS, however current research
has challenged this dogma.
Inflammatory leukocytes infiltrate damaged tissue during the acute periods (1-3
days) following different CNS injuries including stroke, SCI, and traumatic brain injury
(Carlson et al., 1998; Jin et al., 2010; Holmin et al., 1995). In the minutes to hours
following these injuries, the damaged tissue and glial cells secrete proinflammatory
cytokines, such as TNF-α and IL-1 (Witko-Sarsat et al., 2000; Cheret et al., 2008;
Barone et al., 1997; Rothwell et al., 1997). These cytokines induce expression of
adhesion molecules in the adjacent endothelial cells of the BBB and circulating
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inflammatory leukocytes (Qian et al., 2007). The adhesion molecules interact, leading to
rolling of the leukocytes along the vasculature and eventual tight binding to the
endothelium (Yilmaz and Granger, 2008). Once adjacent to the injured tissue, the
leukocytes need to penetrate through the BBB basal membrane, which includes
collagen, fibronectin, and laminin (Scholz et al., 2007). MMP-9 has the capability to
degrade these molecules and may have a role in diapedesis of neutrophils. In this
study, we demonstrated that neutrophils contain MMP-9 shortly after NTx (Figures 3.2 &
3.3), which is observed in other models of CNS injury (Larsen et al., 2003; Lee et al.,
2004). Beyond the BBB, neutrophils migrate through the ECM by haptotaxis, a gradient
of insoluble chemoattractants bound to structural components of the matrix (WitkoSarsat et al., 2000). It has been suggested that neutrophils secrete MMP-9 to degrade
components of the ECM, allowing for migration to the injured tissue (Murphy et al.,
1991). However, Mandeville et al. (1997) demonstrated an alternate method in which
neutrophils can reversibly distort the structural component of the ECM and squeeze
through gaps in the matrix without proteolytic degradation. This process has been
termed “amoeboid-type” migration (Wolf et al., 2003). However, this does not exclude
the possibility that, depending on the environment, the structural component of the ECM
can be either flexible or tight (Itoh, 2006). MMP-9 may have a role in the migration
through the tight ECM. Nobel et al. (2002) demonstrated that MMP-9-/- mice have
decreased infiltration of neutrophils following SCI. This suggests that MMP-9 is
important for neutrophil migration from the vasculature to the injured tissue.
Once at the injured tissue, neutrophils secrete oxidative enzymes and
proinflammatory cytokines. These molecules may promote a secondary trauma to the
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surrounding tissue, although this has yet to be conclusively determined (Emerich et al.,
2002). The oxidative enzymes, including myeloperoxidase and NADPH oxidase,
increase the levels of oxygen free radicals, resulting in increased intracellular calcium
and cell damage (Arnhold and Flemmig, 2010). In addition to these enzymes,
neutrophils secrete MMP-9 at the site of injury, which may damage healthy neurons.
MMP-9 cleaves components of myelin and adhesive molecules important for neuronECM interaction, leading to apoptosis of the neuron (Gijbels et al., 1993; Zalewska et
al., 2002). MMP-9 may also exacerbate the inflammatory response of the injured tissue.
IL-8, an inflammatory cytokine, is cleaved by MMP-9 at the N-terminus (Gijbels et al.,
1993; Van Den Steen et al., 2000). This truncated molecule is a strong stimulus for
neutrophils, leading to an increased inflammatory response. While MMP-9 may serve
some beneficial roles in CNS injury and recovery, its overall activity may be inhibitory to
neuronal recovery. MMP-9-/- mice have improved functional recovery following different
CNS injury models, confirming that MMP-9 is detrimental to CNS recovery (Lee et al.,
2004; Noble et al., 2002).
Macrophages represent the chronic inflammatory response and are often
measured in injured tissue for weeks or months following injury (Dusart and Schwab,
1994; Fleming et al., 2006). CD68 positive cells, associated with the phagocytic
phenotype of macrophages, infiltrate the transected bulb by day 3 following injury and
are observed through day 10 (Figure 3.4). The corresponding CTRL bulb at each
recovery period did not have detectable levels of CD68. This suggests that CD68 cells
are involved in an injury-related process. Figure 3.5 demonstrated that CD68 positive
macrophages do not contain MMP-9. There are conflicting reports regarding the
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expression of MMP-9 by macrophages which may be related to morphologic changes of
these cells (Anthony et al., 1997; Fleming et al., 2006; Larsen et al., 2003). Unlike the
short-lived neutrophils, macrophages undergo multiple morphologic phenotypes during
their lifetime in damaged tissue (Adams and Hamilton, 1984). Therefore, macrophages
may contain MMP-9 only during specific phenotypic stages, such as transmigration from
the vasculature. Further studies are needed to determine if other macrophage
phenotypes contain MMP-9.
Conclusion. This is the first report to demonstrate that neutrophils are a source
of MMP-9 in the OB following NTx. Neutrophils infiltrated the injured bulb during the
acute period (days 1-15) after injury, while CD68 positive macrophages gradually
entered the NTx bulb by day 3. Although CD68 macrophages do not contain MMP-9,
this does not exclude the possibility that other macrophage phenotypes express MMP9. Future studies with MMP-9-/- mice can determine the role of MMP-9 in neuronal
degeneration, inflammation and its potential as a therapeutic target to improved
recovery.
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Chapter 4
Matrix Metalloproteinase-9 and -2 Expression in the Olfactory Bulb Following
Methyl Bromide Gas Exposure

4.1 Introduction
Matrix metalloproteinases (MMPs) are a family of over 20 structurally related
enzymes comprised of a propeptide and a Zn2+-binding catalytic domain. These
enzymes are implicated in the degradation of extracellular matrix (ECM) components
including laminin, collagen IV, and elastin (Yong, 2005). In normal physiological
processes, such as angiogenesis, wound healing, learning and memory, MMPs serve
an important role in the remodeling of the ECM (Nagase and Woessner, Jr., 1999;
Yong, 2005). Though their enzymatic action is necessary for tissue restructuring and
repair, the MMPs are highly regulated due to their potential destructive capability
towards the ECM. Most MMPs are secreted as zymogens and require cleavage of the
prodomain and association of a Zn2+ in the catalytic domain to become fully activated.
Studies have shown that uncontrolled activation of these enzymes can result in certain
pathologies including arthritis, multiple sclerosis and Alzheimer’s disease (Yong et al.,
1998; Yoshihara et al., 2000).
In the central nervous system (CNS), several MMPs are modulated after
neuronal injury. Two specific MMPs, MMP-9 and MMP-2, have defined temporal
expression patterns following different models of neuronal injuries (Romanic et al.,
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1998; Rosenberg et al., 1996; Wang et al., 2000; Wang et al., 2002). For example, after
SCI, MMP-9 expression increased within hours whereas MMP-2 expression was
delayed for up to a week (de, Jr. et al., 2000; Goussev et al., 2003). The early presence
of MMP-9 correlates with inflammation, degradation of blood vessel walls, edema and
neuronal death. The delay in MMP-2 expression is important for remodeling the ECM
and breakdown of scar, ensuring the proper conditions necessary for neuronal recovery
(Hsu et al., 2006; Goussev et al., 2003; Zuo et al., 1998).
We have previously reported the expression of MMP-9 and MMP-2 following
direct trauma to olfactory neurons using a NTx injury model. In this model, the axons
are lesioned as they penetrate through the cribriform plate before entering the olfactory
bulb. The NTx injury is not limited to the axons alone but also injures other CNS
structures including the anterior-ventral portion of the bulb and blood vessels. Following
NTx, there is a temporal expression of these two specific MMPs, similar to other CNS
neuronal injuries. MMP-9 is elevated within hours following NTx whereas MMP-2 levels
did not increase until a week after injury (Costanzo et al., 2006; Costanzo and Perrino,
2008). The temporal expression of these two enzymes provides insight into the
molecular processes associated with olfactory degeneration and regeneration. Though
the expression of MMP-9 and MMP-2 in CNS injury has been established, these models
involve some component of trauma. It is unknown if MMP-9 and MMP-2 are upregulated
in the absence of direct trauma or toxic injury, i.e. by deafferentation alone.
Unlike most models of CNS injury, the olfactory system is unique in that the cell
bodies of sensory neurons are located outside the CNS, in the peripheral olfactory
epithelium and project their axons to the olfactory bulb, a CNS structure. This
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organization allows for the study of direct (NTx) injury to the CNS vs. isolated
deafferentation via the destruction of the neuronal population. The latter is achieved
through methyl bromide gas (MeBr) exposure. MeBr is passively inhaled, filling the
nasal cavity and leading to destruction of over 90 percent of cells in the olfactory
epithelial, including olfactory neurons (Schwob et al., 1995). This leads to
deafferentation of the olfactory bulb without direct trauma.
In this study we examined the expression levels of MMP-9 and MMP-2 in the
olfactory bulb following MeBr exposure to determine if these MMPs are associated with
neuronal deafferentation in the absence of direct CNS trauma. A comparison of findings
from both these indirect (MeBr) and direct (NTx) CNS injury models provides a new
approach to investigating the role of MMPs in neuronal injury and recovery processes.

4.2 Materials and Methods
Methyl bromide gas exposure. Adult C57/BL6 mice were exposed to MeBr gas
as previously described (Chen et al., 2004; Schwob et al., 1995). Mice were placed in a
wire enclosure measuring 15 X 15 X 15 cm centered within a plexiglass box measuring
30 X 30 X 30 cm and exposed to 180 ppm MeBr gas in purified air at a flow rate of 10L
per hour for six hours. Mice exposed to room air served as controls (CTRL). All
procedures were approved by the Institutional Animal Care and Use Committees of
Virginia Commonwealth University and Tufts University School of Medicine.
Tissue sampling and preparation. At 1, 3, 5, 7, 10, 15, 40 and 60 days after
MeBr gas exposure, mice were anesthetized with sodium pentobarbital and sacrificed
by rapid decapitation. The OBs were removed from the skull, flash frozen in liquid
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nitrogen and processed as previously described (Costanzo et al., 2006). The anteriorventral portion of the bulbs and samples from frontal cortex were removed for protein
measurements. All tissue samples were placed in protein extraction buffer (50 mM TrisHCl, 150 mM NaCl, 1% NP-40, 1% sodium dodecylsulfate, 1% DOC) and homogenized
with a motor-driven plastic homogenizer. The tissue was incubated on a rotating
platform at 4oC for 30 minutes, homogenized and centrifuged at 4 oC for 30 minutes at
16,000 rpm. Samples were then placed in a minus 80oC freezer for storage. Solubilized
proteins in the supernatant were quantified using DC protein assay reagent kit (Bio-Rad
Laboratories, Hercules, CA) using bovine serum albumin as a standard. Protein
measurements were made at 750 nm on a μQuant plate reader (BioTek Instruments
Inc., Winooski, VT). Equal amounts of protein (20 μg for MMP-9 and 40 μg for MMP-2)
from the tissue extracts and purified murine MMP-9 and MMP-2 (R and D Systems,
Minneapolis, MN) were loaded onto 4-12% Bis-Tris density gradient gels and separated
using NuPAGE MES [2-(N-morpholino) ethane sulfonic acid] reducing buffer system
(Invitrogen, Carlsbad, CA) for 1 hour at 200 V and 4oC. Protein was transferred to
nitrocellulose membrane for 2 h at 25V and 4oC. 5% bovine nonfat dry milk in Trisbuffered saline and 0.05% Tween-20 was used to block nonspecific binding for 1 hour.
Goat anti-MMP-9 and Goat anti-MMP2 (1:200, R and D Systems), goat anti-OMP
(1:20000, Wako Chemicals, Richmond, VA), and rabbit anti-glial fibrillary acidic protein
(1:50000, DakoCytomation, Glostrup, Denmark) primary antibodies were used. Rabbit
anti-CPA (1:7000, Upstate, Lake Placid, NY) primary antibody was obtained to control
for protein loading. Nitrocellulose membranes were incubated in the primary antibody
overnight at 4oC. Membranes were then exposed to the appropriate species
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peroxidase-conjugated IgG secondary antibody (Rockland, Gilbertsville, PA) for 1 hour.
The membranes were incubated for 1 minute in Western Lightning Plus reagent (Perkin
Elmer, Wellesley, MA) and exposed to Blue Sensitive Autoradiography film
(ThermoScientific, Rockford, IL).
Protein

measurements.

Quantification

of

protein

expression

on

the

nitrocellulose membrane was performed using Quantity One Analysis software (Bio-Rad
Laboratories). The protein bands were measured both by band density and band area.
The density-area measurements for MMP-2, MMP-9, OMP and GFAP at each recovery
time point were then divided by the corresponding density-area measurement for CPA
in the same gel to adjust for differences in protein loading. These protein ratios were
then divided by CTRL samples to obtain normalized expression levels.
Immunohistochemistry. Immunohistochemical staining for MMP-9 and MMP-2
was performed on horizontal sections at 3 different time points after MeBr: days 1, 5
and 10. After washing with Invitrogen Phosphate Buffered Saline (PBS) for 10 minutes,
sections were placed in 0.01M Citric acid with steam for 10 minutes, and washed in
PBS for 10 minutes. Sections were then immersed for 1-minute intervals in a series of
alcohol solutions (70%, 95%, 100%, 95%, 70%) and placed in PBS wash for 5 minutes.
This was followed by incubation with 10% normal rabbit serum, 4% bovine serum
albumin, 5% non-fat dry milk and 0.5% Triton X-100 in PBS for 1 hour and placed with
goat anti-MMP-9 or goat anti-MMP-2 primary antibody (1:10) overnight. Sections were
then incubated in peroxidase-conjugated rabbit anti-goat immunoglobulin (1:50) and
exposed to 3, 3’-diaminobenzidine (DAB, Vector Laboratories, Inc., Burlingame, CA).
Sections were counterstained with Harris Modified Hematoxylin (Fisher Scientific, Fair

76

Lawn, NJ) and visualized on an Eclipse E600 microscope (Nikon Inc., Melville, NY).
MMP-9-labeled cell counts. Digital images of immunostained histological
sections were used to obtain cell counts of MMP-9 positive cells located within different
layers of the olfactory bulb. For each olfactory bulb section, the total number of MMP-9
positive cells was counted within each of four defined regions: the combined nerve and
glomerular layer, the external plexiform layer, the combined mitral and internal plexiform
layer, and the granular cell layer. The criteria used to define a MMP-9 labeled cell was:
positive DAB staining and visualization of the cell nucleus. Three separate bulb sections
were used to obtain the mean number of cells for each region. We also measured the
average area (mm2) for each bulb region using ImageJ analysis software (National
Institutes of Health, MD).
Statistical analysis. A comparison of protein levels at each of the different
recovery time points relative to CTRL was performed using 2-Way ANOVAs and a
Holm-Sidak 2-sided post-hoc test. A probability of less than 0.05 was considered
statistically significant. All statistical analysis was performed using SPSS software (IBM,
Chicago, IL).

4.3 Results
MMP-9 and MMP-2 protein expression was measured in the olfactory bulb
shortly after MeBr gas exposure (day 1) and during neuronal degeneration (day 1-15)
and regeneration (day 15-60) time periods. Western blot analysis of MMP-9 and MMP-2
expression following MeBr is shown in Figure 4.1. Density-area measurements of MMP
protein bands were compared with that of CPA (Figure 4.1A) to determine the relative
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amounts of MMP-9 and MMP-2 in the bulb at each time point. The mean values
normalized to CTRL levels from 4 separate experiments are plotted in Figure 4.1B and
C. In CTRL samples, MMP-9 expression was absent and MMP-2 levels were barely
detectable. MMP-9 remained at CTRL levels during the first 3 days, increased rapidly
between days 3 and 5, and reached maximum expression, 33-times higher than CTRL
values, at day 5. MMP-9 remained elevated for 2 weeks after MeBr then returned to
CTRL by day 40. MMP-2 expression was low in CTRL animals and remained near
CTRL following MeBr injury, though an increase in expression (2.1-times higher than
CTRL) was detected on day 5.
To determine if the MeBr injury leads to a widespread activation of MMP-9 in the
CNS, we monitored MMP-9 expression in the frontal cortex (Figure 4.2). At
each recovery time point, MMP-9 expression in frontal cortex remained at CTRL levels,
suggesting that the MeBr injury response was limited to the olfactory system in contrast
with other systemically administered toxins (Colin-Barenque et al., 2008). This finding is
consistent with other studies of MeBr injury (Schwob et al., 1995).
In addition to MMP expression, we monitored changes in OMP and glial fibrillary
acidic protein (GFAP) within the olfactory bulb (Figure 4.3). OMP, a protein expressed in
mature olfactory neurons, was used to monitor deafferentation and subsequent
reinnervation of the bulb. The mean OMP values from four separate experiments
normalized to CTRL levels are plotted in Figure 4.3A. OMP reached its lowest levels by
day 15, corresponding to deafferentation of the bulb. By day 40, OMP levels had
increased approaching CTRL levels, indicating reinnervation of the bulb by regenerated
olfactory neurons.
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Figure 4.1: Changes in MMP-9 and MMP-2 protein expression in the OB following
MeBr15

Figure 4.1: Changes in MMP-9 and MMP-2 protein expression in the OB following
MeBr. A. Representative Western blots illustrating changes in MMP-9 and MMP-2
expression at different time points following injury. Lane 1 shows purified murine MMP-9
and MMP-2 standards (STD). Lane 2 shows an absence of MMP-9 and minimal
detection of MMP-2 in CTRL tissue. CPA bands for each lane were used as controls for
protein loading. B&C. Plots of the relative amounts of MMP-9 and MMP-2 expressed as
a percentage of CPA and normalized to CTRL levels. MMP-9 increased rapidly on day
5, reaching 33 times the expression levels in CTRL samples. MMP-9 remained elevated
for 10 days and then returned to CTRL levels by day 40. MMP-2 expression was
detectable but at low levels following injury. At day 5, MMP-2 expression was increased
two fold above background CTRL levels. The doublet bands in the MMP-2 Western blot
represent the pro and active forms of MMP-2. Data points represent the mean
normalized to CTRL ± SEM (n=4 for each time point). ANOVA analysis with a HolmSidak post hoc for each time point compared to CTRL is given in Table 4.2. CPA:
cyclophilin A; CTRL: control; MeBr: methyl bromide gas; OB: olfactory bulb.
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Figure 4.2: Comparison of MMP-9 expression in the OB and frontal cortex following
MeBr16

Figure 4.2: Comparison of MMP-9 expression in the OB and frontal cortex following
MeBr. Bar graphs represent the relative amount of MMP-9 expressed as a ratio of CPA
normalized to CTRL levels. The expression of MMP-9 in the olfactory bulb (black)
remains at CTRL levels through day 3 following MeBr. Between days 3 and 5, MMP-9
levels increase rapidly and reach maximum expression. MMP-9 levels begin to
decrease by day 7 and return to CTRL levels by day 40. In the frontal cortex (grey),
MMP-9 expression did not increase above CTRL levels. Data points represent the mean
normalized to CTRL ± SEM (n=4 for each time point). CTRL: control; MeBr: methyl
bromide gas; OB: olfactory bulb.
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Monitoring GFAP levels allowed for the assessment of reactive gliosis following
injury. GFAP is an intermediate filament protein present within astrocytes that increases
in response to CNS injury (Silver and Miller, 2004). Mean values of GFAP normalized to
CTRL levels from four separate experiments are plotted in Figure 4.3B. After MeBr gas
exposure, GFAP expression remained near CTRL levels through day 3. GFAP levels
increased by day 10 and achieved maximal expression at day 15. By day 40, GFAP
expression started to decrease, although at day 60 was still slightly elevated.
Histological sections of the olfactory bulb following MeBr injury are shown in
Figure 4.4. The low power image (Figure 4.4A) provides orientation to the distinct
morphological layers of the bulb. Figure 4.4B shows immunohistochemical staining for
MMP-9 and MMP-2 during the degeneration of pre-existing olfactory axons (days 1, 5,
and 10). No MMP-9 signal was detected on day 1, confirming the Western blot analysis.
At day 5, MMP-9 immunoreactivity was observed in cells in all regions of the bulb,
though the cells labeled with MMP-9 were highly concentrated in the olfactory nerve and
glomerular layers where the olfactory axons traverse and terminate, respectively (Figure
4.4B & Table 4.1). By day 10, MMP-9 immunoreactivity decreased although still
detectable within the bulb. MMP-2 labeled cells were not observed at any of the three
time points. The combination of 3, 3’-diaminobenzidine (DAB) and hematoxylin staining
(Figure 4.5A & B) was used to demonstrate that MMP-9 was localized to neutrophils,
which were identifiable on the basis of their lobulated nuclei.
Table

4.2

shows

2-way

ANOVA

and

Holm-Sidak

post-hoc

analysis

demonstrating the Western blot recovery time points that are significant compared to
CTRL levels for MMP-9, MMP-2, OMP, and GFAP expression.
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Figure 4.3: Changes in OMP and glial fibrillary acidic protein in the OB following
MeBr17

Figure 4.3: Changes in OMP and glial fibrillary acidic protein in the OB following MeBr.
Plots represent relative amount of protein for OMP and glial fibrillary acidic protein
(GFAP) expressed as a ratio of CPA normalized to CTRL levels in four separate
experiments. A. OMP is a marker for degeneration and regeneration of olfactory
neurons. OMP levels declined slowly following MeBr injury, reaching a minimum at day
15, indicating deafferentation of the bulb. By day 40 OMP begins to increase towards
CTRL levels, corresponding to reinnervation of the bulb. B. GFAP, representing
astrocytic activation and gliosis, remained low until day 5, slowly increased and reached
a maximum level at day 15. Data points represent the mean normalized to CTRL ± SEM
(n=4 for each time point). ANOVA analysis with a Holm-Sidak post hoc for each time
point compared to CTRL is given in Table 4.2. CPA: cyclophilin A; CTRL: control;
GFAP: glial fibrillary acidic protein; MeBr: methyl bromide gas; OB: olfactory bulb; OMP:
olfactory marker protein.
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Figure 4.4: Coronal sections of the mouse OB following MeBr18

Figure 4.4: Coronal sections of the mouse OB following MeBr. A. Diagram (left)
illustrates approximate location of histological images. Image (right) shows the different
anatomical layers of the olfactory bulb. B. Images stained for MMP-9 and MMP-2 at
recovery days 1, 5 and 10. MMP-9 expression was not observed at day 1. MMP-9
labeled cells were detected in all layers of the OB, concentrated within the NL and GL at
day 5. Fewer MMP-9 labeled cells were observed at day 10. MMP-2 labeled cells were
not observed at day 1, 5 or 10. EPL: external plexiform layer; GCL: granular cell layer;
GL: glomerular layer; IPL: internal plexiform layer; MeBr: methyl bromide gas; MCL:
mitral cell layer; OB: olfactory bulb; ONL: olfactory nerve layer.
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Figure 4.5: Localization of MMP-9 to inflammatory cells in the OB at day 519

Figure 4.5: Localization of MMP-9 to inflammatory cells in the OB at day 5. A&B: At low
magnification (40x), MMP-9 labeled cells are observed in the NL and GL of the OB.
Lower panels: At high magnification (60x), MMP-9 labeling was observed in neutrophils,
having the characteristic polymorphic nuclei. Arrows in A and B (low magnification)
identify cells shown below at high magnification. GL: glomerular layer; NL: nerve layer;
OB: olfactory bulb.
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Table 4.1: Average number of MMP-9 labeled cells and areas of OB layers Table
Bulb Layer
NL & GL
EPL
ML & IPL
GCL

Day 1
15.0 ± 3.0
5.0 ± 1.7
1.7 ± 0.6
2.7 ± 2.1

Day 5
236.0 ± 29.8
72.0 ± 3.6
10.3 ± 2.1
49.0 ± 8.9

Day 10
39.3 ± 11.8
17.3 ± 10.5
3.3 ± 2.5
9.7 ± 6.5

Area (mm^2)
0.171 ± 0.029
0.163 ± 0.050
0.057 ± 0.025
0.187 ± 0.096

OB: olfactory bulb; NL: nerve layer; GL: glomerular layer; EPL: external plexiform layer;
ML: mitral layer; IPL: internal plexiform layer; GCL: granule cell layer
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Table 4.2: Table summarizing the significant Western blot recovery points compared to
CTRL for MMP-9, MMP-2, OMP, and GFAP Table 1
MMP-9
p

MMP-2
p

OMP
p

GFAP
p

D1

0.679

0.934

0.907

0.755

D3

0.995

<0.001

0.205

0.866

D5

<0.001

0.258

0.103

D7

0.014

0.313

0.056

D10

0.139

0.120

0.199

0.001

D15

0.032

0.102

0.002

D40

0.948

0.217

0.134

0.008

D60

0.905

0.003

0.136

0.102

Recovery

**
*
*

<0.001
0.040

**
**
*

**

*: p<0.05; **: p<0.01

91

**

<0.001

**
**
**

4.4 Discussion
Comparison of the two injury models. Following trauma, the CNS uses
different mechanisms to prevent further injury and to initiate a recovery process.
However, some mechanisms may be important for only a specific component of injury
such as neuronal deafferentation. Most CNS injury models include both deafferentation
and direct trauma and therefore are unable to distinguish between the two. This limits
our understanding of how the CNS responds to and resolves deafferentation vs. direct
trauma. The olfactory system offers a unique opportunity to assess mechanisms
following both deafferentation (MeBr) and direct traumatic injury (NTx) in the CNS.
These two olfactory injury models result in deafferentation followed by a reinnervation of
the olfactory bulb. MeBr is a peripheral deafferentation injury for which there is no direct
lesion to the CNS since the olfactory epithelium is separated from the bulb by the bony
cribriform plate. In contrast NTx injury includes direct trauma to CNS tissue including the
olfactory bulb and nerve layer in addition to bulb deafferentation. Comparing these two
injury models allows for the identification of processes associated with deafferentation
and/or trauma. Expression of MMPs in both injury models suggests they play a common
role in deafferentation of the olfactory bulb.
MMPs in CNS injury. Recovery from CNS injury requires the remodeling of the
ECM and breakdown of scar tissue for successful recovery. MMPs have become the
focus of recent studies of neuronal injury due to their ability to degrade many prominent
components of the ECM and scar. Previous reports have demonstrated MMP-9 and
MMP-2 have temporal expression patterns following different CNS trauma models
including olfactory NTx, spinal cord injury, and stroke suggesting an important role in
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neuronal injury and recovery (Costanzo et al., 2006; Costanzo and Perrino, 2008; de,
Jr. et al., 2000; Romanic et al., 1998). MMP-9 expression increases early in response to
these CNS injuries, corresponding to inflammation, vascular breakdown, edema, and
neuronal death. The inflammatory leukocytes are co-localized with MMP-9. These cells
may use MMP-9 to penetrate the blood vessel walls and migrate through the ECM to
reach the site of injury (Busch et al., 2009; Fleming et al., 2006; Rosell et al., 2008).
MMP-9 has also been shown to disrupt the ECM and neuronal connections, leading to
neuronal degeneration and death (Gu et al., 2002; Siebert et al., 2001). MMP-2
expression increases within a week following many CNS injuries. This corresponds to
the reparative phases of neuronal recovery when MMP-2 participates in the remodeling
of the ECM, digests scar components, and participate in angiogenesis (Hsu et al., 2006;
Montaner et al., 2001; Zuo et al., 1998).
The inhibition of these enzymes has demonstrated the importance of MMPs in
the injury and recovery process. In the absence of MMP-9 there is improved recovery in
stroke injury models whereas the inhibition of MMP-2 is detrimental to neuronal
recovery (Asahi et al., 2001; Hsu et al., 2006; Lee et al., 2004; Noble et al., 2002). The
modulation and temporal expression of MMP-9 and MMP-2 during olfactory injury and
recovery provides potential targets for therapeutic intervention and improved outcome.
MMPs in olfactory injury and recovery. In this report, we demonstrate
increased MMP-9 and MMP-2 expression in the olfactory bulb after MeBr exposure
(Figure 4.1). Between days 3 and 5, MMP-9 rose rapidly and reached expression levels
33-times higher than in CTRL samples at day 5. This increase following MeBr is isolated
to the olfactory system, as demonstrated by the absence of MMP-9 expression in the
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frontal cortex following MeBr exposure (Figure 4.2), confirming that MeBr injury does
not have a diffuse MMP response in the CNS. The increase in MMP-9 expression in
MeBr injury is delayed when compared to the 5 hour increase with direct CNS injury
such as olfactory NTx. This delay in MMP-9 expression may reflect the time necessary
for the degeneration process to reach the axon terminals within the bulb. In contrast, the
rapid response of MMP-9 following NTx could be due to

components of direct injury

specifically vascular disruption and trauma to CNS structures such as the anteriorventral surface of the bulb. With vascular injury, components of clotting cascade are
increased, including tissue-plasminogen activator (tPa) and urokinase plasminogen
activator (uPa), both known regulators of MMP-9 expression (Menshikov et al., 2002;
Wang et al., 2003). Since MeBr injury occurs within the olfactory epithelium, a site
distant from the olfactory bulb, bleeding is unlikely to occur within the CNS, and
therefore, vascular-induced MMP-9 expression is not expected.
The constellation of findings in the olfactory bulb after MeBr exposure are similar
in many respects to direct CNS injury (i.e., NTx), and therefore, MMP-9 may be playing
a common role.

During the initial recovery period following neuronal injury, two

processes that rely on MMP-9, glial scar formation and leukocyte infiltration, are
increased at the site of injury (Hsu et al., 2008). We demonstrated that MMP-9 is
localized to neutrophils concentrated in the region of the injured nerve axonal
projections following MeBr (Figures 4.4, 4.5, & Table 1). This suggests that the signal
for MMP-9 expression is the deafferentation injury. MMP-9 may allow these
inflammatory leukocytes to penetrate through the vascular wall and ECM to reach and
degrade the injured axons. Likewise following MeBr injury, astrocytic activation is
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observed within the bulb as demonstrated by high levels of GFAP at day 10 and in
previous immunohistochemical analysis (Schwob et al., 1999). The increased
expression of GFAP paralleled the elevated levels of MMP-9. This association is also
demonstrated following olfactory NTx, where GFAP increased 3 days following injury
during elevated MMP-9 expression. This suggests similar processes are involved in
both MeBr and NTx, leading to increases in MMP-9 expression.
MMP-2 expression was detectable but low in both CTRL and MeBr injury
samples, though a 2-fold increase was observed on day 5. Low levels of MMP-2
detection may reflect its constitutive expression in the CNS (Rosenberg, 2002). The
response of MMP-2 following MeBr is minimal compared to NTx, where up to a 20-fold
increase in expression has been reported (Costanzo and Perrino, 2008). This dramatic
increase in MMP-2 following NTx occurs 7 days after injury, corresponding to the
transition between deafferentation and reinnervation of the bulb. In MeBr injury, this
transformation was observed between days 15 and 40, as demonstrated by changes in
OMP (Figure 4.3A). The transition between deafferentation and reinnervation of the bulb
following MeBr is delayed compared to NTx and may explain the relatively low MMP-2
expression in our MeBr injury model. The small increase in MMP-2 at day 5 may
represent changes in the olfactory bulb with second order neurons, specifically the
mitral and tuft cells. As mitral and tuft cells synaptic connections are lost in the
glomerular layer, these neurons may secrete MMP-2 in order to modify the ECM in an
attempt to create new synapses. Further work will be necessary to determine if MMP-2
is being expressed by the regenerated first order neurons, or the second order neurons,
in an attempt to create new synaptic connections.
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Conclusion. A comparison of MeBr and NTx injury models has proven useful in
uncovering important information underlying neuronal injury and recovery in the
olfactory system. In both injury models, we demonstrated an early expression of MMP-9
corresponding to inflammatory processes. This suggests that, regardless of the
mechanism of injury, inflammation is a key component of neuronal injury and recovery.
Though the importance of MMP-2 is still unclear, we did observe differences in the
timing of MMP-2 expression between the two injury models. This is the first report
demonstrating that MMP-9 expression is associated with deafferentation in the absence
of direct trauma. Further studies are needed to determine the underlying mechanisms
and contributions of MMP-9 and MMP-2 to neuronal injury and recovery processes.

96

Chapter 5
The Peak Expression of MMP-2 Following Nerve Transection is Dependent on
Reinnervation of the Olfactory Bulb

5.1 Introduction
In Chapter 2, MMP-2 expression peaked sharply at day 7 following NTx,
suggesting an important process is occurring at this time point (Figure 2.8). Previous
reports have localized MMP-2 expression to macrophages, glial cells, and neurons in
the normal and injured CNS (Anthony et al., 1997; Planas et al., 2001). Following NTx,
both macrophages (Chapter 3: Figure 3.4) and gliosis (Costanzo 2006) are increased in
the NTx bulb by day 3, suggesting that these processes may not be responsible for the
peak expression of MMP-2. Therefore, MMP-2 may be related to regenerated axons
initially contacting the bulb at day 7. The time course of neuronal degeneration and
recovery in the bulb has been previously defined by monitoring OMP expression, a
marker for mature sensory neurons (Chapter 2: Figure 2.3). Following NTx, OMP levels
decreased at day 1 and remained below CTRL levels through day 10, signifying the
degeneration of sensory axons. By day 15, OMP expression increased back to CTRL,
indicating regenerated axons penetrating the OB. However, reinnervation of the OB is
likely to occur before this period, as the transition from immature and mature neurons
may take up to a week (Miragall and Monti Graziadei, 1983). This suggests that
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immature axons may initially contact the bulb at day 7 but delay expressing OMP until
day 15.
This chapter has two objectives: 1) determine the source of MMP-2 in CTRL and
day 7 NTx bulbs, and 2) establish a relationship between MMP-2 and regenerated
axons at day 7. The hypothesis of the first objective is that MMP-2 will be expressed by
resident neurons (granular cells and second order neurons) in both CTRL and day 7
NTx bulbs. At day 7, regenerated axons in the bulb will also express MMP-2, leading to
the peak expression observed. The hypothesis of the second objective is that the peak
expression of MMP-2 at day 7 will be attenuated if regenerated axons are blocked from
reaching the bulb. Blockage of sensory axons will be accomplished by insertion of a
Teflon barrier following NTx. These experiments will identify the cellular source of MMP2 and begin to uncover the importance of this MMP in neuronal injury and recovery.

5.2 Materials and Methods
NTx surgical procedure. Adult P2-IRES-tau-lacZ mice were anesthetized with
sodium pentobarbital (80 mg/kg, intraperitoneal). After anesthesia, the left OB was
exposed and a thin Teflon cutting blade was inserted between the left bulb and the
cribriform plate. The use of a Teflon blade resulted in transection of all the olfactory
axons that connect to the left bulb, and minimal damage to the bulb and cribriform plate.
After transection, the skin incision was sutured and each animal was observed
postoperatively before returning to its cage. The right bulb was not transected and
serves as an internal CTRL for histological analysis.
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Teflon barrier surgical procedure. The NTx protocol was performed as
described above. Following NTx, a thin piece of Teflon was inserted between the left
bulb and cribriform plate. The skin incision was sutured, leaving the barrier in place until
the animal was sacrificed. All procedures were approved by the Institutional Animal
Care and Use Committee of Virginia Commonwealth University.
Immunohistochemistry.
performed

on

CTRL

and

Immunohistochemical

day

7

NTx

bulbs.

staining

Hematoxylin

for
and

MMP-2

was

eosin

and

immunohistochemical staining for MMP-2 and GAP-43 were performed on nerve
transection with Teflon barrier (NTx-TB) bulbs at day 7. Mice were anesthetized with
sodium pentobarbital and perfused with saline followed by 4% paraformaldehyde (INC
Biomedicals, Inc., Aurora, OH). The skull was removed and placed in 4%
paraformaldehyde for 30 minutes, then rinsed with tap water for 5 minutes and
immersed in Decal overnight (Decal Chemical Corp, Tallman, NY). The following day,
skulls were placed in PBS containing 30% sucrose for a week then frozen in a minus
80oC freezer. Horizontal sections were cut on a Microm HM 550 series Cyrostat
(MICROM International GmbH, Walldorf, Germany) and placed on Superfrost® Plus
VWR® Micro Slides (VWR, West Chester, PA). The slides were stored in a minus 20oC
freezer until processed.
The slides were allowed to reach room temperature before washing with
Invitrogen (Carlsbad, CA) phosphate-buffered saline (PBS) for 10 minutes. Microwave
antigen retrieval was performed as previously described (Stone et al 1999) with some
modifications. Sections were heated to 65oC for 8 minutes and allowed to cool for 20
minutes at room temperature. After washing 3 times in PBS, the slides were blocked
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and permeabilized for 1 hour in a solution containing 10% normal donkey serum
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA) and 0.2% Triton X-100
(LabChem Inc. Pittsburgh, PA) in PBS. The sections were incubated with primary
antibody in blocking solution overnight: goat anti-MMP-2 (1:10; R&D Systems,
Minneapolis, MN) and rabbit anti-GAP-43 (1:500; Novus Biologicals. Littleton, CO). The
following day the slides were washed 3 times in PBS and placed in the species
appropriate donkey secondary antibody. MMP-2 was visualized with CY3 conjugated
donkey anti-goat (1:100; Jackson ImmunoResearch, Inc., West Grove, PA) and GAP-43
visualized with AlexaFluor 488 conjugated donkey anti-rabbit (1:100; Invitrogen). The
slides were analyzed on an Eclipse E600 microscope (Nikon Inc, Melville, NY).
Western blot tissue sampling and preparation. At 5 hour and 1, 3, 7, 10, 15,
and days after surgery, mice were anesthetized with sodium pentobarbital and killed by
rapid decapitation. The left OB tissue was carefully removed along with left bulb tissue
from CTRL animals (receiving no surgical treatment). Although the right bulb of
transected mice serves as internal CTRL, occasionally some injury is observed in this
bulb. Therefore, CTRL animals were used to ensure that no injury was present in CTRL
samples. Left bulbs were immediately placed in protein extraction buffer (50 mM TrisHCl, 150 mM NaCl, 1% NP-40, 1% sodium dodecylsulfate, 1% DOC) and homogenized
with a motor-driven plastic homogenizer. The tissue was incubated on a rotating
platform for 20 minutes at 4°C and centrifuged at 16 000g for 30 minutes at 4°C.
Solubilized proteins in the supernatant were quantified with a DC protein assay reagent
kit (Bio-Rad Laboratories, Hercules, CA), using bovine serum albumin as a standard.
Protein measurements were made at 720 nm on a μQuant plate reader (BioTek
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Instruments Inc., Winooski, VT). Equal protein samples and purified murine MMP-2
(Chemicon, San Francisco, CA) were loaded onto Bis-Tris 4–12% density gradient gels
and separated using NuPAGE MES [2-(N-morpholino) ethane sulfonic acid] reducing
buffer system (Invitrogen) for 1 hour at 200 V and 4°C. Protein was transferred to
nitrocellulose membranes for 2 hours at 25 V and 4°C. Nonspecific binding was blocked
with 5% bovine nonfat dry milk in Tris-buffered saline and 0.05% Tween-20 for 1 hour.
Goat anti-MMP-2 primary antibody (1:200) was obtained from R&D Systems. Goat antiOMP (1:20,000; Wako Chemicals, Richmond, VA) was used as a marker of axonal
degeneration and regeneration in the bulb. Rabbit anti-CPA (1:5000; Upstate, Lake
Placid, NY) antibody was used to standardize protein loading. Nitrocellulose
membranes were incubated overnight in primary antibody at 4°C. Membranes were
then treated with species-specific peroxidase-conjugated IgG secondary antibodies
(Rockland, Gilbertsville, PA), incubated for 1 minute with Western Lightning Plus
reagent (Perkin Elmer, Wellesley, MA) and exposed to Blue Sensitive Autoradiography
film (Marsh BioProducts, Rochester, NY).
Protein measurement. Quantification of protein expression was performed
using Quantity One Analysis software (Bio-Rad Laboratories). Protein expression was
measured as a function of both band density and band area. This density–area
measurement for MMP-2 and OMP at each recovery time point was then standardized
against the corresponding density–area measurement for CPA in the same gel. The
protein measurement of MMP-2 or OMP was then expressed as a ratio of CPA (amount
of protein divided by amount of CPA) and then normalized to CTRL levels (amount of
protein/CPA ratio divided by amount of CTRL protein/CPA ratio).
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Statistical analysis. Protein levels at each of the Western blot recovery time
points were compared to CTRL values using 2-way ANOVA and a Holm-Sidak 2-sided
post hoc test. A probability of less than 0.05 was considered statistically significant. All
statistical analysis was performed using SPSS software (IBM, Chicago, IL).

5.3 Results
MMP-2 localization in CTRL and day 7 NTx bulbs. To determine the cellular
source of MMP-2 expression, immunohistochemical analysis was performed on CTRL
and NTX (day 7) bulbs (Figure 5.1). In the CTRL bulb, MMP-2 was apparent in the deep
granule cell layer. This layer is composed mainly of granule cells (small inhibitory
neurons) and glial cells. At high power, MMP-2 is observed in long processes that
extend from the deep layers of the bulb, through the external plexiform layer and
terminate in the glomerular layer. Contained in the external plexiform layer are the
dendrites of second order neurons (mitral and tufted cells) and glial cells. In the day 7
bulb, MMP-2 was localized to the granule cell and external plexiform layers, similar to
the CTRL bulb. MMP-2 was not apparent along the anterior aspect of the bulb, where
injured tissue is observed or the nerve and glomerular layers, the location of
regenerated axons.
Teflon barrier. To determine if MMP-2 expression is associated with
reinnervation of the OB, a Teflon barrier was inserted between the cribriform plate and

102

Figure 5.1: Comparison of MMP-2 labeling in CTRL and transected OB20

Figure 5.1: Comparison of MMP-2 labeling in CTRL and transected OB. In the low
power image, MMP-2 is apparent throughout the GCL of the CTRL OB. MMP-2 is also
observed in the EPL. High power of the EPL shows MMP-2 expression in long
processes (arrow) extending through this layer and terminating in the glomerular layer
(GL). The day 7 NTx OB at low power shows a similar pattern of MMP-2 labeling
compared to CTRL. MMP-2 expression is apparent in the GCL, however is not seen
along the anterior aspect of this layer. This portion of the bulb is damaged during the
NTx procedure and contains injured tissue. High power image of the EPL shows MMP-2
in processes extending from the EPL to the GL, similar to the CTRL image. CTRL:
control; EPL: external plexiform layer; GCL: granule cell layer; GL: glomerular layer;
NTx: nerve transection; OB: olfactory bulb. Scale bars: low magnification: 100 μm; high
magnification: 50 μm.
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OB. This barrier serves to block regenerated axons as they pass through the cribriform
plate. Figure 5.2A shows the site of Teflon barrier insertion between the bulb and
cribriform plate. Occasionally, the barrier fell off the slide during tissue processing,
leaving a blank space (Figure 5.2A right panel).
As axons reach the barrier, they are unable to contact the bulb and change their
path (Figure 5.2B arrows). Some axons are seen circumventing the block along the
medial and lateral edges of the barrier (Figure 5.2B asterisks).
To verify that the Teflon barrier was successful at blocking regenerated axons
from reaching the bulb at the gross level, whole mount preparations were compared
between NTx and NTx-TB bulbs at day 35 (Figure 5.3). The Teflon barrier was inserted
between the anterior OB and cribriform plate. The barrier does not encompass the
entire bulb, and therefore, it is not seen in the medial view of the whole mounts (Figure
5.3B). Regenerated P2 axons are evident in the anterior portion of the day 35 NTx bulb.
In contrast, the NTx-TB mice have considerable depletion of P2 axons in the bulb.
Axons that are blocked converge along the anterior aspect of the barrier (Figure 5.3B
asterisks). Some axons are observed circumventing the barrier and penetrate the OB
(Figure 5.3B arrows).
To confirm that the Teflon barrier blocked the majority of regenerated sensory
axons, OMP expression was monitored by Western blot (Figure 5.4). OMP initially
decreased between days 1 and 3 following NTx-TB and remained below CTRL levels
through day 15 (Figure 5.4B). This indicates the degeneration of sensory axons. In
contrast, OMP expression increased by day 15 following NTx (Figure 5.4C). This
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Figure 5.2: Teflon barrier blocks regenerated axons from contacting the OB21

Figure 5.2: Teflon barrier blocks regenerated axons from contacting the OB. A.
Horizontal sections at day 7 show the site of Teflon barrier insertion between the
cribriform plate and OB. The left panel illustrates the barrier in a horizontal section.
During tissue processing, the barrier occasionally fell off the slide, leaving a blank space
(right panel). B. High power images comparing the trajectory of sensory axons in CTRL
and NTx-TB OB. Sensory axons normally pass through the cribriform plate projecting
directly to the NL and terminate on the GL (left two panels). The right panels
demonstrate that the insertion of a Teflon barrier prevents the axons from contacting the
bulb. The axons that originate from the anterior epithelium appear to alter their path at
the barrier (arrows). Some axons are observed bypassing the block and contacting the
OB along the medial and lateral aspects of the barrier (asterisks). CTRL: control; GL:
glomerular layer; NL: nerve layer; NTx-TB: nerve transection with Teflon barrier; OB:
olfactory bulb. Scale bar: A. 500 μm; B. 100 μm.
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Figure 5.3: Comparison of P2 axonal projections at day 35 following NTx or NTx-TB22

Figure 5.3: Comparison of P2 axonal projections at day 35 following NTx or NTx-TB. A.
Diagram comparing horizontal views of the NTx and NTx-TB. The Teflon barrier (red) is
inserted between the cribriform plate and OB. The barrier encompasses only the
anterior portion of the bulb and therefore it is not seen in the medial view in the whole
mount images. B. Whole mount preparations showing the differences in P2 axonal
projection in NTx (left) and NTx-TB (right). P2 axons are apparent in the bulb following
NTx and converge onto multiple glomeruli by day 35. In NTx-TB, most of the P2 axons
are blocked from entering the bulb. These blocked axons are observed along the
cribriform plate, in front of the barrier (asterisks). Some axons are seen bypassing the
barrier and penetrate the bulb (arrow). NTx: nerve transection; NTx-TB: nerve
transection with Teflon barrier; OB: olfactory bulb. Scale bar: 500 μm.
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demonstrates that the barrier was successful at blocking the initial reinnervation of the
OB in NTx-TB mice. Between days 15 and 35, OMP expression in the NTx-TB mice
increased towards CTRL, indicating that some regenerated axons bypassed the barrier
and penetrated the bulb
Having established that the Teflon barrier successfully blocked regenerated
axons, MMP-2 expression was measured by Western blot analysis (Figure 5.5). In
CTRL animals, MMP-2 levels were detectable. Following NTx-TB, a 5-fold increase in
MMP-2 expression was observed, which was sustained through day 35 (Figure 5.5B). In
contrast, a large peak in MMP-2 levels was evident at day 7 following NTx (Figure
5.5C). This indicates that the peak expression of MMP-2 at day 7 is associated with
regenerated neurons contacting the bulb.
To determine if regenerated axons contain MMP-2, immunohistochemical analysis of
MMP-2 and growth associated protein-43 (GAP-43) was performed on day 7 NTx-TB
bulbs. GAP-43 is a molecule expressed in the growth cone of developing and
regenerated axons. At day 7, histological analysis demonstrates sensory axons
immediately anterior to the barrier (Figure 5.6 H&E low power and high power). GAP-43
is expressed by these axons, signifying that they are regenerated and migrating towards
the OB. However, MMP-2 was not observed in the area of the axons, indicating that
MMP-2 is not contained in regenerated axons following NTx-TB.
Table 2.1 shows the ANOVA and Holm-Sidak post-hoc analysis indicating the
Western blot recovery time points that are significant compared to CTRL levels for OMP
and MMP-2 expression.
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Figure 5.4: Changes in OMP expression following NTx-TB23

Figure 5.4: Changes in OMP expression following NTx-TB. A. Representative Western
blot illustrating OMP expression at different recovery time points. CPA levels serve as a
gel loading CTRL. B. Plot of the mean OMP expression, normalized to CTRL levels,
from four separate Western blots. Following NTx-TB, OMP levels remain near CTRL
through day 1. By day 3, OMP expression decreased, indicating degeneration of
sensory neurons. This decrease continues through day 15, when OMP levels are
minimal. Between days 15 and 35, OMP levels increase, suggesting some of the
regenerated axons bypass the barrier. C. In NTx, OMP expression was increased by
day 15, signifying regenerated axons penetrating the bulb. This indicates that the barrier
successful at blocking the initial regenerated axons from reaching the bulb. Data points
represent the mean ± SEM (n=4 at each time point). ANOVA analysis with a HolmSidak post hoc for each time point compared to CTRL is given in Table 5.1. CPA:
cyclophilin A; CTRL: control; NTx: nerve transection; NTx-TB: nerve transection with
Teflon barrier; OMP: olfactory marker protein.
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Figure 5.5: Expression of MMP-2 following NTx-TB24

Figure 5.5: Expression of MMP-2 following NTx-TB. A. Representative Western blot
showing changes in MMP-2 expression at different recovery time points in the bulb.
Lane 1 contains purified pro and active murine MMP-2. CTRL lane demonstrated
detectable levels of MMP-2. CPA levels serve as a gel loading CTRL. B. Plot of the
mean expression of MMP-2, normalized to CTRL levels, of four separate Western blots.
A 5-fold increase in MMP-2 expression is detected as early as 5 hours following NTxTB. This levels was sustained through the recovery time period measured. C. In NTx,
there was a large peak in MMP-2 expression observed at day 7. This suggests that the
peak in MMP-2 expression following NTx is dependent on regenerated sensory axons in
the OB. Data points represent the mean ± SEM (n=4 at each recovery time point).
ANOVA analysis with a Holm-Sidak post hoc for each time point compared to CTRL is
given in Table 5.1. CPA: cyclophilin A; CTRL: control; NTx: nerve transection; NTx-TB:
nerve transection with Teflon barrier.
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Figure 5.6: Regenerated axons do not express MMP-2 following NTx-TB25

Figure 5.6: Regenerated axons do not express MMP-2 following NTx-TB. Three
examples (A, B, C) showing axons (asterisk) projecting from the OE to the Teflon barrier
(TB) at day 7. The high power images demonstrate the sensory axons (asterisks) that
are analyzed in the immunohistochemical images. The sensory axons are labeled with
growth associated protein-43 (GAP-43: green), a marker for growing axons, signifying
that these axons projecting to the TB are regenerated. MMP-2 expression (red) was not
observed to colocalize with GAP-43, indicating that regenerated axons do not express
MMP-2 as they project to the TB. The immunofluorescent analysis (GAP-43 and MMP2) was performed on sections 10 μm adjacent to the histological sections (low and high
power). GAP-43: growth associated protein-43; OE: olfactory epithelium; TB: Teflon
barrier. Scale bars: low magnification: 1 mm; high magnification: 10 μm.
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Table 5.1: Table summarizing the significant Western blot recovery points compared to
CTRL for OMP and MMP-2 Table 2

Recovery

OMP
p

MMP-2
p

5H

0.516

0.007

D1

0.553

0.003

D3

0.329

0.009

D7

0.011

D10

0.054

D15

0.001

D35

0.088

*

0.017
0.004

**

0.050
0.042

**
**
**
*
**
*
*

*: p<0.05; **: p<0.01
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5.4 Discussion
Based on emerging data that MMP-2 plays an important role in neuronal
recovery, it was hypothesized that MMP-2 is expressed by regenerated axons following
NTx. Immunohistochemical analysis demonstrated that MMP-2 is observed in the
granule cell and external plexiform layers in CTRL mice. Although the Western blot of
MMP-2 demonstrated a large peak at day 7 following NTx, surprisingly the histological
analysis failed to show differences in MMP-2 labeling between CTRL and day 7 bulbs.
To determine if there is a relationship between the large peak in MMP-2 expression and
regenerated axons reaching the bulb at day 7, a Teflon barrier was inserted between
the cribriform plate and OB following NTx. This barrier was successful at blocking the
initial innervation of the bulb by regenerated axons. The peak in MMP-2 expression was
not observed in NTx-TB bulbs. MMP-2 did not localize to the regenerated axons,
suggesting that regenerated axons may trigger processes in the OB that increase the
expression of MMP-2 at day 7.
MMP-2 expression in CTRL and day 7 NTx bulbs. The olfactory bulb is a
highly dynamic structure that requires constant remodeling of the ECM. In normal mice,
there is constant turnover of sensory neurons and synaptic connections with second
order neurons (e.g. mitral and tufted cells). The deep layer of the OB is also dynamic
with small inhibitory neurons, called granule cells, continuously replaced by neuroblasts
derived from the subventricular zone of the cortex (reviewed in Curtis et al., 2009).
These cells migrate along the rostral migratory stream to the granule cell layer of the
OB. The turnover of these two neuronal populations likely involves the remodeling of the
ECM. In CTRL animals, MMP-2 was localized to cells in the granule cell layer and
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processes extending through the external plexiform layer to the glomerular layer (Figure
5.1). As the granule cells migrate along the rostral migratory stream and enter the
granule cell layer of the bulb, they may express MMP-2 to degrade components of the
ECM. This would allow these neurons to easily migrate to their target tissue. The
constant renewal of sensory axons leads to turnover of synaptic connections with
second order neurons in the glomerular layer. MMP-2 may have an important role in
dendrite migration through the external plexiform layer to establish synaptic connections
with new sensory axons.
An alternative source of MMP-2 expression in the granule cell and external
plexiform layers may be the glial cells. In the normal CNS, glial cells, specifically
astrocytes, express MMP-2 (Cuzner et al., 1996). Astrocytes are found throughout the
CNS, including the OB and play a role in synaptic pruning and remodeling (Barres,
2008; Christopherson et al., 2005; Stevens et al., 2007). The high turnover of neurons in
the CTRL bulb likely requires constant modulation of synapses, in which MMP-2 may
have an important role.
Histological analysis failed to show differences in MMP-2 labeling between the
CTRL and day 7 NTx bulbs. This is surprising because a large peak in MMP-2
expression was measured at day 7 by Western blot (Figure 5.5C). Western blot analysis
is a measure of the global changes in protein levels, i.e. samples are taken from the
antero-ventral OB. In contrast, immunohistochemical analysis examines a small portion
(10 μm) of the OB. There may be subtle changes in MMP-2 expression in the granule
cell and external plexiform layers that are undetectable by immunohistochemistry.

119

Teflon Barrier. To determine if the peak expression of MMP-2 at day 7 is
dependent on reinnervation of the OB, regenerated axons were blocked with a Teflon
barrier. Regenerated axons travel along a very narrow and defined course, having to
pass through the small foramina of the cribriform plate. A barrier can be inserted
anterior to the OB, which blocks the axons as they emerge from the cribriform plate.
The Teflon barrier was successful at blocking regenerated neurons from reaching the
OB. In histological images, blocked sensory axons were evident along the anterior edge
of the barrier (Figure 5.2), while whole mount preparations showed the majority of P2
axons did not reach the OB after 35 days recovery (Figure 5.3). Western blot analysis
demonstrated that OMP expression reached a minimum at day 15 following NTx-TB
(Figure 5.4). In contrast, OMP levels increased by day 15 following NTx, indicating
reinnervation of the OB. Taken together, these experiments indicate that the placement
of the Teflon barrier between the cribriform plate and OB was successful at blocking
regenerated axons. With the NTx-TB injury model established, MMP-2 expression was
monitored by Western blot (Figure 5.5). An injury-related increase in MMP-2 was
observed following NTx-TB and remained at this level through the time period
measured.

This indicates that the peak expression of MMP-2 following NTx is

dependent on regenerated axons reaching the OB. Immunohistochemical analysis
demonstrated that the regenerated axons do not contain MMP-2 following NTx-TB
(Figure 5.6). This suggests that the regenerated axons may trigger processes in the OB
that increase MMP-2 expression. MMP-2 may modify the ECM to create a supportive
environment for regenerated axons to reestablish synaptic connections with second
order neurons. Since MMP-2 has the capability to degrade many prominent
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components of the ECM, is seems likely that it has an important role neuronal recovery.
However, further studies aimed at targeted disruption of MMP-2 are needed to
determine the importance of MMP-2 in olfactory injury and recovery.
Conclusion. The results presented in this study demonstrate that the peak
expression of MMP-2 at day 7 following NTx is dependent on regenerated axons
reaching the OB. However, MMP-2 was not expressed by the regenerated axons. In
CTRL and day 7 NTx bulbs, MMP-2 was localized to the granule cell layer and
processes extending through the external plexiform layer to the glomerular layer. This
suggests that MMP-2 is found in resident cells of the bulb (e.g. granule cells, second
order neurons, and glial cells). These resident cells may increase the expression of
MMP-2 at day 7 to remodel the ECM, providing a supportive environment for
regenerated axons to reestablish functional synapses. Future studies aimed at targeted
disruption of MMP-2 are needed to determine the role of MMP-2 in neuronal injury and
recovery and to assess its potential as a target for therapeutic intervention.
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Chapter 6
General Discussions

6.1 Summary of important findings
This project uncovered differences in the temporal expression of MMP-9 and
MMP-2 following 3 olfactory nerve injury models (Figure 6.1). These injury models: 1)
nerve transection (NTx), 2) methyl bromide gas (MeBr) exposure, and 3) nerve
transection with Teflon barrier (NTx-TB), produced different degrees of CNS trauma and
neuronal recovery. The changes in MMP-9 and MMP-2 in each model revealed a
temporal correlation between MMP expression and neuronal degeneration and
reinnervation of the OB.
Chapter 2 presented data that MMP-9 increased immediately in the OB following
NTx and remained elevated for two weeks (Figure 2.6). The temporal expression of
MMP-9 coincided with decreased OMP expression (Figure 2.3). Chapter 3 presented
evidence that neutrophils were a source of MMP-9 following NTx (Figure 3.2). These
experiments suggest that MMP-9 is associated with both the acute inflammatory
response and neuronal degeneration following NTx. To confirm that the increased
MMP-9 level was associated with neuronal degeneration, the temporal expression of
MMP-9 following MeBr exposure was measured (Chapter 4). MeBr is a toxic compound
that ablates the olfactory epithelium, leading to neuronal degeneration and subsequent
regeneration, without direct trauma to the CNS. Following MeBr exposure, MMP-9
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expression increased in the OB at day 5 and remained elevated through day 15, while
neuronal degeneration was maximal between days 3 and 15 (Figures 4.1B & 4.3A).
MMP-9 was localized to neutrophils primarily in the nerve and glomerular layers of the
OB (Figures 4.4 & 4.5; Table 4.1). The temporal expression and location of MMP-9
corresponded to neuronal degeneration in the OB, demonstrating that MMP-9 is
associated with the degradation of sensory axons.
MMP-2 was constitutively expressed by resident cells in the granule cell and
external plexiform layers of the bulb (Figure 5.1). An injury-related increase in MMP-2
was observed following NTx, with a significant peak apparent at day 7 (Figure 2.8). This
recovery day corresponded to the transition between neuronal degeneration and
reinnervation of the OB (Figure 2.3). To determine if the day 7 peak in MMP-2
expression was dependent on regenerated axons in the OB, a Teflon barrier was
inserted between the OB and cribriform plate. The Teflon barrier successfully blocked
the initial reinnervation of the bulb at day 7 (Figures 5.2, 5.3, & 5.4) and, consequently,
MMP-2 levels did not peak (Figure 5.5B). This demonstrated that the peak levels of
MMP-2 following NTx are dependent on the reinnervation of the OB at day 7.
Surprisingly, MMP-2 was not localized to the regenerated axons (Figure 5.6). Therefore,
regenerated axons contacting the OB likely trigger processes that increase expression
of MMP-2 at day 7.
This is the first study to associate the temporal relationship of MMP-9 with
neuronal degeneration and MMP-2 with reinnervation of the OB by comparing 3
olfactory injury models. Future studies aimed at targeted disruption of MMP-9 and
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Figure 6.1: Diagram illustrating the temporal correlation between MMP-9 and
degeneration, and MMP-2 and the onset of reinnervation26nd the onset of
reinnervation27

Figure 6.1: Diagram illustrating the temporal correlation between MMP-9 and
degeneration, and MMP-2 and the onset of reinnervation. In all 3 injury models (A, B, &
C), increased MMP-9 levels (blue) correlated with neuronal degeneration (red). In NTx
injury (A), a large peak in MMP-2 (grey) expression was observed at day 7 and
correlated with the transition between degeneration and reinnervation (green). In MeBr
injury (B), the transition from degeneration to reinnervation occurred between days 15
and 35, recovery time periods not studied (shaded area). In the NTx-TB model (C),
regenerated axons were blocked from reaching the OB and MMP-2 expression
remained low. The absence of a MMP-2 peak in NTx-TB suggests that the peak is
dependent on reinnervation of the OB. MMP-2 (grey) is constitutively expressed in
control bulbs and present prior to each injury (arrow). MeBr: methyl bromide gas; NTx:
nerve transection; NTx-TB: nerve transection with Teflon barrier; OB: olfactory bulb.
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MMP-2 can determine the role of these two MMPs following olfactory injury and may
uncover novel therapeutic targets to improve neuronal recovery

6.2 Future Directions
This report describes the temporal correlation of MMP-9 with neuronal
degeneration and MMP-2 with the initial transition to recovery. However, the functional
role of these two MMPs remains unclear. Future studies aimed at targeted disruption of
expression or activity can determine the significance of the MMP-9 and MMP-2 in
olfactory injury and recovery. Studies with gene knockout mice have demonstrated
important roles for MMP-9 and MMP-2 in other models of CNS injury. Following both
stroke and spinal cord injuries, MMP-9-/- mice have improved functional recovery (Lee et
al., 2004; Noble et al., 2002). In contrast, MMP-2-/- mice have diminished neuronal
recovery after SCI (Hsu et al., 2006). Behavioral studies with wild-type, MMP-9-/-, and
MMP-2-/- would be a simple way to determine whether these MMPs contribute to
neuronal recovery following olfactory injury. If either MMP is important for neuronal
regeneration, then genetic knockout would attenuate the detection and discrimination of
odors following olfactory injury. In addition, changes to the topographical map can be
monitored with the development of a P2-tau lacZ/MMP-/- mouse. This mouse would
demonstrate changes in the topographical map compared to wild-type mice following
injury, depending on the role of MMP-9 and MMP-2 in neuronal recovery.
Other MMPs in olfactory injury and recovery. Accumulating evidence points
towards other MMPs having important roles in CNS injury and recovery. The findings
from this present study can direct future research towards other MMPs that may have
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important role in olfactory neuronal regeneration. Previous studies have shown that the
prodomain of MMP-9 is cleaved by MMP-3 (stromalysin-1), a key step in the activation
of MMP-9 (Ogata et al., 1992; Rosenberg et al., 2001). This represents a possible
mechanism for MMP-9 activation following olfactory injury. In other models of CNS
injury, including SCI and traumatic brain injury, MMP-3 increased early and was
localized to glial cells and apoptotic neurons (Falo et al., 2006; Grossetete et al., 2009;
Kim et al., 2005). MMP-3 can induce the generation of inflammatory cytokines and
recruitment of inflammatory cytokines and may represent an early trigger for the
inflammatory response (Kim et al., 2005). As the initial inflammatory leukocytes infiltrate
the injured tissue, MMP-3 can activate MMP-9 secreted by neutrophils. MMP-3-/- and
MMP-9-/- mice have similar neuroprotection following global ischemia, suggesting that
that MMP-3 may be key regulator of MMP-9 in vivo or has a similar role in neuronal
injury and recovery (Walker and Rosenberg, 2009).

Another

MMP

that

may

be

present following olfactory injury is MT1-MMP, an important activator of MMP-2. The
mechanism of converting latent MMP-2 to the active form by MT1-MMP has been
previously described (Chapter 1, section 1.2.2). Following NTx, both the pro and active
forms of MMP-2 are increased in the OB at day 7. Therefore, it can be logically
assumed that MT1-MMP will be located in the bulb following injury. MT1-MMP is also
known to be important in cellular migration and processing of cell adhesion molecules,
however its importance in neuronal degeneration and recovery in the CNS has yet to be
investigated (Itoh, 2006).
The infiltration of neutrophils into the injured bulb represents another source for
MMPs following olfactory injury. The granules of neutrophil contain both MMP-9 and
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MMP-8 (neutrophil collagenase) and secrete these MMPs in response to injury (ToftHansen et al., 2004; Murphy et al., 2002). To this point, the study of MMP-8 in the CNS
has been limited to the inflammatory response following injury. Finally, research has
started to focus on MMP-12 as an important protein for CNS injury and recovery. Buss
et al. (2007) demonstrated that MMP-12 increased in response to SCI and was
localized to macrophages. MMP-12-/- mice have improved neuronal recovery after injury.
Although still in its beginning stages, MMP-12 research represents renewed interest into
the importance of MMPs in the CNS.

6.3 Significance of this project
This project represents the first steps in understanding the molecular
mechanisms important for olfactory injury and recovery. Currently, it is estimated that
over two million people in the Unites States suffer from olfactory disorders (Hoffman et
al., 1998; Costanzo and Zasler, 1992). Olfactory dysfunction can be dangerous, with
patients unable to detect dangers such as smoke, gas leaks, or spoiled food (Seiden,
1997; Santos et al., 2004). Up to 40 percent of patients have experienced a hazard
event due to an olfactory disorder (Santos et al., 2004). In addition, people with
impaired olfactory function are more likely to report a diminished quality of life and suffer
from depression (Miwa et al., 2001; Deems et al., 1991). Currently, there are limited
treatment options for olfactory dysfunction, leading to frustration of clinicians and often
misunderstanding of olfactory problems. Determining the molecular mechanisms
important for olfactory injury can lead to future research modulating these processes,
perhaps leading to improved neuronal recovery. Based on previous studies, modulation
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of MMP-9 and MMP-2 leads to increased neuronal recovery. Therefore, future studies
aimed at targeted disruption of these two MMPs may reveal novel therapeutic options
for patients suffering from olfactory dysfunction.
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